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ZUSAMMENFASSUNG 
 
Das Nierenzellkarzinom umfasst eine heterogene Gruppe von Tumoren, die zusammen ca. 90% 
aller Tumore der humanen Niere ausmachen. Die häufigste histologische Untergruppe stellt 
dabei das klarzellige Nierenzellkarzinom (ccRCC) dar. Zunehmend mehr Beweise zeigen, dass 
das Immunsystem ccRCC erkennt und auch kontrollieren kann. Aus diesem Grund werden 
immer mehr immuntherapeutische Strategien zur Behandlung dieser Patienten getestet. 
Immuntherapie mit immunstimulierenden Zytokinen, wie IL-2 und IFN-, zeigen eine moderate 
therapeutische Wirkung in einigen Patienten, jedoch stellt die damit zusammenhängende 
schwerwiegende systemische Toxizität ein Problem dar. 
Zellen des adaptiven Immunsystems erkennen so genannte Tumor-assoziierte Antigene (TAAs). 
Hierbei handelt es sich um Proteine, die mehr oder weniger selektiv (über)-exprimiert in 
transformierten Zellen vorliegen. Das Verstärken der spontanen TAA-spezifischen Immunität in 
Krebspatienten ist eine Strategie mit geringer Toxizität, mit der in manchen Patienten schon eine 
klinische Wirkung erreicht werden konnte. Aus diesem Grund haben wir die Expression von 
TAAs in Tumorgewebe von ccRCC Patienten analysiert und untersucht, ob eine spontane TAA-
spezifische T Zellantwort in diesen Patienten detektierbar ist. Wir konnten feststellen, dass Cyclin 
D1 (CCND1) häufig in ccRCCs überexprimiert vorliegt und dass in den meisten Patienten auch 
eine CCND1-spezifische CD8+ T Zellantwort existiert. Somit konnten wir zeigen, dass CCND1 
ein potentielles therapeutisches Target für ccRCC darstellt. 
Die Etablierung eines immunoregulatorischen Milieus in Tumoren, welches eine anti-Tumor 
Immunantwort supprimiert, ist sehr wahrscheinlich ein Grund, warum spontane und Therapie-
induzierte Immunität oftmals nicht erfolgreich ist in der Eliminierung von Tumoren. Um Parameter 
zu identifizieren, die in der Immunregulierung des ccRCCs eine Rolle spielen, haben wir eine 
retrospektive Analyse für verschiedene Immunantwort-relevante Gene in Formalin-fixiertem, 
Paraffin-eingebettetem Tumormaterial von primären ccRCCs durchgeführt. Starke Expression 
von CD68 (Makrophagen) und FoxP3 (regulatorische T Zellen) korrelierten signifikant mit 
verkürztem Überleben. Wir konnten feststellen, dass Tumor-assoziierte Makrophagen (TAMs) in 
ccRCC Tumoren einen Phänotyp aufweisen, der charakteristisch ist für M2 (alternativ aktivierte) 
Makrophagen, welcher zum Teil durch die Tumorzellen induziert wird. Darauf folgende 
Experimente auf frischem Patientenmaterial zeigten, dass Tumor-infiltrierende T Zellen co-
inhibitorische Moleküle und Zytokine stärker exprimieren als entsprechende T Zellen aus dem 
Blut. Zudem konnten wir beobachten, dass diese Veränderungen in Phänotyp und Funktion in 
autologen CD4+ T Zellen aus dem Blut vom Tumor-assoziierten Milieu und von FACS-isolierten 
TAMs ausgelöst werden. Unsere Ergebnisse deuten darauf hin, dass ccRCCs zunehmend 
Makrophagen anziehen und eine Veränderung der Makrophagen in Richtung M2 TAMs 
bewirken. Diese M2 TAMs verändern Funktion und Phänotyp von Tumor-infiltrierenden T Zellen 
in der Hinsicht, dass regulatorische Funktionen auf Kosten von Effektorfunktionen zunehmen. 
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SUMMARY 
 
Renal cell carcinoma is a heterogeneous group of tumors that encompass about 90% of all 
tumors of the human kidney, with clear cell renal cell carcinoma (ccRCC) as the major 
histological subgroup. There is growing evidence that the immune system recognizes and can 
control ccRCC and different immunotherapeutic strategies are being investigated as treatment for 
these patients. Immunotherapy using immunostimulatory cytokines such as IL-2 and IFN-
resulted in modest therapeutic efficacy in some patients, however, concomitant severe 
systemic toxicity is a problem.  
Cells of the adaptive immune system recognize so-called tumor-associated antigens (TAAs), 
which are proteins that are more or less selectively (over)-expressed by transformed cells. 
Boosting spontaneous TAA-specific immunity in cancer patients is a strategy with low toxicity, 
which was shown to result in objective clinical responses in some patients. We therefore 
analyzed the expression of TAAs in tumor tissues of ccRCC patients and investigated whether 
spontaneous TAA-specific T cell responses were detectable in these patients. We found a 
frequent overexpression of Cyclin D1 (CCND1) in ccRCC tumor samples and in most of these 
patients also a CCND1-specific CD8+ T cell response. Thus, we identified CCND1 as a potential 
therapeutic target. 
The establishment of an immunoregulatory tumor microenvironment that suppresses anti-tumor 
immune responses may be a reason why spontaneous and therapy-induced immunity often is 
not successful in eradicating the tumor. To identify parameters involved in immunoregulation in 
ccRCC we performed a retrospective analysis on formalin-fixed paraffin-embedded tumor 
material of primary ccRCC for different immune response-related genes. High transcript levels of 
CD68 (macrophages) and FoxP3 (regulatory T cells) correlated significantly with reduced 
survival. We observed that tumor-associated macrophages (TAMs) in ccRCC tumors have a 
phenotype, which is characteristic for M2 (alternative activated) macrophages and which in part 
is induced by tumor cells. Prospective experiments on fresh patient material revealed that tumor-
infiltrating T cells expressed higher levels of co-inhibitory molecules and cytokines than paired 
blood T cells. Furthermore, the tumor-associated milieu as well as FACS sorted TAMs induced 
deviation towards a more regulated phenotype and function of autologous, blood-derived CD4+ T 
cells. Our results suggest that ccRCC progressively attracts macrophages and induces their 
skewing into M2 TAMs. These in turn subvert the function and phenotype of tumor-infiltrating T 
cells such that regulating functions are increased at the expense of effector functions. 
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1.  INTRODUCTION 
 
Immune response-related molecules that are relevant to the experiments presented in this thesis 
are highlighted in bold throughout the introduction, when mentioned and explained first time. 
 
 
1.1  Immunosurveillance of cancer 
 
A German surgeon, Wilhelm Busch of Bonn, described in 1866 the spontaneous remission of 
cancer after an attack of erysipelas, which is now known as a severe skin infection by 
Streptococcus pyogenes, a Gram-negative bacterium. Inspired by this observation, doctors tried 
to induce erysipelas in cancer patients of whom some were cured. Without being aware of these 
discoveries in Europe, William Coley, who worked as a surgeon in New York, noticed a similar 
correlation between the development of erysipelas and spontaneous cure of cancer in patients 
with sarcomas. In 1891, he deliberately infected the first patients with S. pyogenes, which 
resulted in complete and long-lasting remission of cancer. From 1893 onwards, William Coley 
used heat-killed S. pyogenes, which he later mixed with Serratiamarcescens, a Gram-negative 
bacterium, based on publications from a French scientist (G.H. Roger). This mix is known as 
Coley’s Toxin or Coley’s Fluid (1, 2). The mode of action of Coley’s Toxin was not understood in 
the 19th century, but we now think that administration of agents that mimic an infection acted as a 
strong adjuvant and enabled proper induction of tumor-specific immunity in a proportion of cancer 
patients.  In 1909, Paul Ehrlich was the first to suggest that cancers would arise more frequently 
in long-lived organisms if the immune system would not protect us from tumor outgrowth (3). 
Almost 50 years later, Frank Macfarlane Burnet and Lewis Thomas revised the hypothesis of 
immune protection against cancer based upon the enhanced understanding of immunity and the 
demonstration of the existence of tumor cell-specific neo-antigens (4, 5). They introduced the 
concept of cancer immunosurveillance, a hypothesis proposing that the immune system identifies 
and eliminates abnormal self-cells, including cells that are infected, transformed or carry genetic 
alterations. The cancer immunosurveillance hypothesis was seriously challenged by the fact that 
cancers develop in immunocompetent individuals and that immunodeficient, athymic nude mice 
were not more susceptible to chemically induced cancers (6, 7). The functional demonstration of 
tumor-associated antigens (TAAs) in mice further supported the cancer immunosurveillance 
theory (8) and finally in the 1990s improved mouse models of immunodeficiency clearly 
demonstrated a role of the adaptive and the innate immune system in tumor control (9, 10). The 
increased incidence of tumors found in immunosuppressed patients (11, 12), the detection of 
spontaneous immune responses in cancer patients (13, 14), and the favorable impact of tumor-
infiltrating lymphocytes (TILs) on prognosis in some cancer types (15, 16) additionally supported 
the concept of cancer immunosurveillance.  
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1.2 Induction of an effective anti-tumor immune response 
 
Based on our current knowledge three steps must take place for the induction of protective anti-
tumor immunity, as illustrated in Figure I-1. 
 
Figure I-1: Three steps are needed to enable an effective immune response 
1) TAA-uptake and -processing of activated DCs, 2) production of protective T cell responses 3) 
overcoming local immunosuppression (figure from (17)). 
 
1) To initiate a protective immune response, steady state or resting dendritic cells (DCs) must 
take up TAAs from dying tumor cells or a therapeutic vaccine. TAAs include cancer-testis (CT) 
antigens (e.g. MAGE, GAGE, and BAGE), overexpressed self-antigens (p53, HER2/neu), 
differentiation antigens (e.g. MART-1/Melan A, gp100, tyrosinase), point mutations of normal 
genes (altered self) (e.g. BCR-ABL, k-ras), and viral antigens (e.g. EBV, HPV) (18, 19). 
Subsequently, DCs process TAAs and present or cross-present TAA-derived peptides in the 
context of MHC class II or MHC class I molecules, respectively (20, 21). DCs then have to travel 
to the T cell zone of the tumor-draining lymph nodes, where they can activate naïve, tumor-
specific T cells. For CCR7:CCL19/21-dependent migration into the T cell zone as well as for 
productive T cell activation, DCs must acquire an activated or mature phenotype, which includes 
the upregulation of co-stimulatory molecules such as CD40, CD70, CD80 and CD86, of certain 
cytokines such as IL-12 and of CCR7 (22). DC maturation usually occurs in the context of 
infections or inflammation, which can be mimicked by so-called adjuvants (23).  
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2) In the draining lymph node, mature DCs present the TAAs on MHC-class I and -class II 
molecules to CD8+ and CD4+ T cells, respectively. While CD45, known as the common leukocyte 
antigen, is expressed by all leukocytes and functions as a tyrosine phosphatase in leukocyte 
signaling, CD3 is part of the T cell receptor (TCR)-complex and therefore specifically expressed 
by T cells. The CD3 molecule is crucial for signal transduction upon TCR ligation in T cells as 
well as in  T cells. T cells with a TAA-specific TCR will be activated through interaction of the 
TCR with the peptide-bound MHC molecule presented by mature DCs. To mount an effective 
anti-tumor immune response, an additional stimulatory signal is needed provided by the 
interaction of T cell co-stimulatory molecules like CD28 with their surface receptors CD80/86 on 
DCs (24). It is crucial for the induction of protective adaptive immunity that antigens are 
presented to naïve T cells by mature DCs, whereas antigen presentation by steady state DCs 
results in robust peripheral T cell tolerance (anergy or deletion) (25, 26) or the generation of 
regulatory T cells (Tregs) (27, 28). It is questionable whether sufficient DC maturation occurs in 
the context of developing tumors and it therefore can’t be excluded that the presentation of TAA 
results in insufficient T cell activation or even in tolerance. Another hurdle for the induction of 
protective adaptive immunity against cancer is the fact that most TAAs are self-molecules that 
induce central tolerance by negative selection of T cells in the thymus. It was shown that even 
tissue-specific antigens including melanocyte-specific antigens (Melan-A, tyrosinase, gp100) (29) 
and CT antigens (30) are expressed in the thymus of healthy individuals and thus presumably 
purge the T cell repertoire of high affinity T cells.  
 
3) Activated TAA-specific T cells, will leave the lymph node and travel to the site of the tumor to 
execute an array of effector functions that aims to destroy cancer cells. Activated CD8+ T cells 
differentiate into cytotoxic T lymphocytes (CTLs) and lyse tumor cells with the help of CD4+ T 
cells and DCs (31). Memory CD4+ and CD8+ T cells and also components of the innate immune 
system such as heat-shock proteins (HSPs) and IFN- are important to maintain protective 
immunity (32). In the tumor microenvironment many different immunosuppressive mechanisms 
can be operative, which prevent immune activation, trigger the “wrong” immune response or 
enable accumulation and expansion of regulatory immune cell types like Tregs and tumor-
associated macrophages (TAMs) (see 1.3-1.5). These immunoregulatory mechanisms have to 
be overcome to mount an effective immune response.  
 
 
1.3 The dual role of the immune system - Immunoediting 
 
Immunosurveillance describes “the immunological protection of the host against the development 
of cancer, resulting from immune effector functions stimulated by immune recognition of either 
stress ligands or antigens expressed on transformed cells” (10). However, it is now well 
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established that immunosurveillance represents only one phase of a complex multistage 
interaction process between immune cells and tumor cells (33-35). The demonstration that 
tumors from immunocompetent hosts are less immunogenic than those from immunodeficient 
hosts suggested that tumors were sculpted by the immune response resulting in less 
immunogenic tumors (36). As a consequence, the immune system promotes the generation and 
outgrowth of tumor variants that escaped immune recognition and elimination. These results put 
forward the cancer immunoediting hypothesis, which considers that tumor-specific immunity 
plays a dual role - mediation of tumor destruction and promotion of tumor growth - during tumor 
development. As illustrated in Figure I-2 immunoediting consists of three phases: elimination, 
equilibrium and escape. Those three phases are thought to proceed sequentially, but in some 
cases cells may directly enter either into equilibrium or escape phase (33). 
 
Elimination 
The elimination phase represents the host-protective cancer-immunosurveillance phase 
(described in 1.1) during which immune cells of the innate and adaptive immune system 
recognize and destroy tumor cells before cancer becomes clinically apparent. Mouse models of 
immunodeficiency provided first insights into the cell types and molecules of the immune system 
involved in this phase (9, 10).  
Rag2-/- mice (deficient of  and  T cells, B cells and NKT cells) subcutaneously injected with 
the chemical carcinogen 3’-methylcholanthrene (MCA) developed sarcomas faster and with a 
higher incidence than wild type mice (36). In the same study the importance of lymphocytes in 
protection of tumor growth was also shown in a model of spontaneous tumor formation. Mice 
lacking either  T cells or  T cells were more susceptible to MCA-induced sarcomas than wild 
type mice revealing that both T cell subsets contribute to anti-tumor defense mechanisms (37).  
Additionally, an increased incidence of MCA-induced sarcomas was observed in mice specifically 
deficient in NKT (38) or NK cells (39), indicative for a role of these cells in anti-tumor immunity. 
The reactions of NK and NKT cells are controlled by inhibitory and activating receptors (32). One 
stimulatory receptor that is of interest in regard to tumor immunology is the lectin-like NKG2D 
homo-dimer, which is expressed on NK cells,  Tcells and CD8  T cells. The ligands for 
NKG2D are the MHC class I chain-related proteins A and B (MICA and MICB) (human) or Rae-1 
(mouse) as well as the UL16 binding proteins (ULBPs) (40, 41). In steady state situations, 
NKG2D ligands are only expressed on the gastrointestinal epithelium of the stomach and large 
intestine, however, they are expressed by stressed epithelia (42) and many epithelium-derived 
tumors including kidney cancer (43-45).  
Furthermore, effector cytokines and enzymes are required for tumor control, which was 
convincingly shown by increased susceptibility to carcinogen-induced tumors of mice deficient for 
IFN-(46), perforin (47, 48) and IL-12 (49). In this line, there is evidence that also granzyme B 
(50) and IL-2 (51) are needed for effective tumor elimination. 
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Figure I-2: The three phases of immunoediting 
Immunoediting consists of the elimination, equilibrium and escape phase (figure from (33)). 
 
 
Equilibrium 
According to the immunoediting concept, the equilibrium phase may follow when the immune 
system fails to eliminate all cancer cells. During this phase, the adaptive immune system keeps 
the remaining tumor cells in check. Experimental proof was provided by a mouse model in which 
tumors were induced by low-dose MCA (52): Occult tumors rapidly grew out when cells of the 
adaptive immune system were depleted or when cytokines that promote adaptive immunity were 
blocked. A correlation of low levels of tumor cells in the bone marrow and protective immune 
memory was observed in a tumor mouse model (53), and similarly also in breast cancer patients 
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(54), which provided evidence for control of dormant tumors by CD8+ T cells (55). Further clinical 
observations that can be explained by equilibrium are, for example a long period between 
successful treatment of the primary tumor and relapse (56), patients who remain free of disease 
despite micrometastasis (57) and development of donor-derived tumors in organ transplant 
recipients (58, 59).  
 
Escape 
When the balance between tumor growth and immunologic control tips in favor of the tumor, 
edited tumor cells that survived the equilibrium phase escape control and become clinically 
apparent. This implies that tumors develop in the face of (insufficient) anti-tumor immunity, which 
is illustrated by the fact that tumor-specific immunity can be measured in many patients with 
clinically apparent cancer (13, 14). 
Tumors can escape the immune control by many different mechanisms (9, 60). The 
immunological pressure can lead to the escape of edited tumor variants with reduced 
immunogenicity. Downregulation of MHC class I molecules (61, 62), impaired TAA processing 
(63), or downregulation of TAA expression (64, 65) can lead to a reduced recognition of tumor 
cells by the adaptive immune system. Similarly, tumors can become unrecognizable for cells of 
the innate immune system through for example the loss of ligands for the NK cell effector 
molecule NKG2D (66). Upregulation of anti-apoptotic molecules or inactive forms of death 
receptors leads to an increased resistance of tumor cells to the lysis by immune cells (67, 68).  
Besides these tumor-intrinsic alterations, subversion of anti-tumor immune responses by the 
establishment of an immunosuppressive tumor microenvironment is another escape mechanism 
(see below, Figure I-3). 
 
 
1.4 Immunosuppressive tumor microenvironment 
 
Tumor cells can acquire multiple mechanisms that lead to the establishment of an 
immunosuppressive microenvironment that hampers or even precludes protective anti-tumor 
immunity. Such mechanisms are for example the production of immunosuppressive factors 
(TGF-, IL-10, VEGF, soluble MICA, IDO), the expression of co-inhibitory molecules (PD-L1, 
HVEM, Galectin-9) that interact with immunoregulatory molecules on T cells (PD-1, BTLA, Tim-3, 
CTLA-4, CD200), the recruitment of immunoregulatroy cell types (Tregs, TAMs, MDSCs), the 
generation of a shift in Th1/Th2 responses and the promotion of chronic inflammation. 
 
INTRODUCTION 
12 
 
 
 
Figure I-3: Tumor escape mechanisms 
Tumors acquire multiple intrinsic and extrinsic mechanisms to elude or inhibit anti-tumor 
immunity (figure from (9)). 
 
 
Immunosuppressive factors released by tumor cells 
Tumor cells can produce and release immunosuppressive soluble factors that inhibit immune 
effector functions or recruit regulatory cell types to generate an immunosuppressive 
microenvironment. Transforming growth factor- (TGF- and IL-10 are regulatory cytokines 
produced by tumor cells that interfere with the activation, maturation and differentiation of both 
innate and adaptive immune cells, leading to impaired anti-tumor immunity (69-71). Another 
regulatory factor released by tumor cells is the enzyme indoleamine 2,3-dioxygenase (IDO) that 
was shown to inhibit T cell proliferation and function by the induction of tryptophan deficiency in 
the tumor microenvironment (72). 
 
Expression of immunosuppressive molecules on tumor cells 
Tumor cells can inhibit the effector functions of immune cells in a cell-contact mediated manner 
by expression of inhibitory ligands on their surface. 
As mentioned before, the activation of T cells requires a primary signal delivered through the 
engagement of the TCR with peptide-bound MHC molecules on antigen-presenting cells (APCs) 
and secondary signals transmitted through interactions of different co-stimulatory and -inhibitory 
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molecules. Co-stimulatory signals are for example delivered through CD28 on T cells with 
CD80/86 on APCs, while the interaction of cytotoxic T lymphocyte antigen 4 (CTLA-4) or 
programmed death 1 (PD-1) on activated T cells with CD80/86 or programmed death ligand 1 or 
2 (PD-L1/PD-L2) on APCs and/or tumor cells inhibits T cell responses (73, 74). CTLA-4 is an 
inhibitory receptor expressed by a variety of immune cells, including activated T cells and Tregs. 
It binds CD80/86 with higher affinity than CD28 and thus can effectively outcompete co-
stimulatory CD28 signaling (75). Furthermore, there is evidence that the engagement of B7 
molecules on the surface of DCs with CTLA-4 on T cells leads to an upregulation of IDO in DCs 
(76) and by this to an activation of the immunoregulatory pathway of tryptophan metabolism often 
associated with increased IL-10 secretion and expansion of Tregs (77). It was shown that the 
expression of PD-L1 progressively increases on leukemic cells, which presumably results in 
progressive resistance to CTL-mediated killing (78). Besides PD-1, also T cell immunoglobulin 
and mucin-domain-containing molecule 3 (Tim-3) contributes to the loss of T effector cell 
function. The ligand for Tim-3, Galectin-9, is expressed by APCs. T cells that express both PD-1 
and Tim-3 represent a cell population in TILs with an increased dysfunctional phenotype 
compared to T cells expressing just one of the molecules (79). 
The role of the herpesvirus-entry mediator (HVEM) expressed on APCs is less clear: by binding 
to B- and T-lymphocyte attenuator (BTLA) the initiation and maintenance of ongoing T cell 
effector functions is inhibited. On the other hand, the engagement of HVEM with its endogenous 
ligand LIGHT can induce stimulatory signals in T cells (80). A recent study in melanoma patients 
showed that tumor-specific CD8+ T cells are rendered dysfunctional by the tumor 
microenvironment through upregulation of the inhibitory receptors BTLA and PD-1. The 
combined blockage of PD-1, Tim-3 and BTLA enhanced the expansion, proliferation, and 
cytokine production of tumor–specific CD8+ T cells (81).  
CD200 has been detected on activated T cells within tumors (82). It is suggested that the 
interaction of CD200 with the CD200 receptor on myeloid cells transmits an inhibitory signal 
leading to a decreased production of Th1 cytokine production and increased IL-10 production 
(83). Furthermore, CD200 is also expressed by tumor cells of hematopoietic (84) and also some 
solid cancers (85) and was shown to be involved in the induction of Tregs (86). 
 
Recruitment of regulatory immune cell types 
Tumors promote the generation, activation and recruitment of immunosuppressive immune cells, 
thus changing the composition of the tumor infiltrate. Regulatory cells attenuate anti-tumor 
immunity through production of immunosuppressive cytokines and alterations in nutrient content 
of the microenvironment.  
Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of cells of myeloid 
origin accumulating in some tumors. They were shown to inhibit both innate and adaptive 
immunity by suppressing CD8+ and CD4+ T cells, NK and NKT cells and by blocking DC 
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maturation (87). Many tumors also attract TAMs that contribute to tumor destruction or promote 
tumor growth depending on their phenotype (introduced in more detail in 1.5). 
Tregs are a subpopulation of CD4+ CD25high T cells that specifically express the transcription 
factor FoxP3 (88). Suboptimal activation of DCs in the tumor microenvironment can lead to the 
generation of immunosuppressive Tregs (27, 28). Also MDSCs are involved in the induction of 
Tregs (89) and TGF- production by tumor cells can convert effector T cells into Tregs (90). 
Tregs secrete the immunosuppressive cytokines IL-10 and TGF- and are known to inhibit the 
effector functions of CD8+ cytotoxic T cells and also NK cells, thereby downregulating cellular 
functions of both the adaptive and the innate immune system (91, 92). It is still not fully 
understood how Tregs block CD8+ T cells, but the expression of CTLA-4 may be involved and 
also IL-2 consumption (90). An increased number of Tregs in the peripheral blood of patients and 
also a tumor infiltrate rich in Tregs showed a correlation with reduced survival of patients 
suffering from different cancer types like ovary, breast and liver cancer (93). 
 
Promotion of a shift in Th1 and Th2 responses 
Tumor progression can be associated with a general shift from Th1 to Th2 immune responses, 
particularly in the tumor microenvironment. 
CD4+ T cells can be divided into different subtypes based on cytokine secretion and chemokine 
expression patterns. While type 1 CD4+ T cells (Th1) provide help to CD8+ T cells and are 
considered to be effector cells with anti-tumor activity (94), type 2 CD4+ T cells (Th2) are besides 
Tregs another subpopulation of CD4+ T cells that polarize immunity away from a beneficial anti-
tumor immunity (95).  
Signal transducer and activator of transcription (STAT) proteins are central in regulating the 
cytokine profile of T cells. The STAT family consists of seven members, each responding to a 
defined set of cytokines and each also regulating the expression of a group of specific genes 
(96). Tyrosine phosphorylation is a critical step in the activation of STAT proteins, often mediated 
by cytokine-receptor associated Janus kinases (JAKs) (97). The development of Th1 and Th2 
cells is induced by the cytokines IL-12 and IL-4/IL-13 respectively. IL-12 can activate STAT-4 
that leads to the differentiation of the Th1 subtype by inducing the production of Th1 cytokines 
like IFN-, whereas IL-4 and IL-13 activate STAT-6 that leads to the development of the Th2 
subtype by inducing the secretion of Th2 cytokines like IL-4, IL-5 and IL-13 (98). STAT-3 is a 
STAT protein important for tumor immune evasion. Abnormal signaling of various growth factor 
receptors like epidermal growth factor (EGF) and vascular epidermal growth factor (VEGF) can 
lead to the persistent activation of STAT-3 in tumor cells. Subsequently STAT-3-driven tumor-
derived factors, like IL-10, IL-6 and VEGF can enhance the activation of STAT-3 in tumor-
associated immune cells (99). STAT-3 in immune cells promotes the development of an 
immunosuppressive environment by mediating the generation of immune suppressor cells, 
including MDSCs, Tregs and Th17 cells, inhibition of DC maturation, negative regulation of Th1-
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type cytokines and enhanced production of immunosuppressive mediators like IL-10 and TGF-
(99). 
 
Tumor-related chronic inflammation and immune regulation 
There is evidence that chronic inflammation may result in malignant transformation (100) and it 
has been suggested that cancer immunoediting and tumor-promoting inflammation are not 
mutually exclusive processes, but may overlap instead (101). 
A relationship between chronic inflammation and carcinogenesis is for example well established 
for the development of hepatocellular carcinoma in consequence of chronic hepatitis (HCC) (102) 
and that lymphotoxin beta receptor (LT-R) signaling represents a pathway involved in 
inflammation-induced HCC (103). The proinflammatory cytokines lymphotoxin alpha (LT-) and 
lymphotoxin beta (LT-) are expressed by activated T-, B-, NK- and lymphoid tissue inducer cells 
and are under normal conditions crucial for organogenesis and maintenance of lymphoid tissues 
(104). Furthermore, lymphotoxin expression on T cells is required for DC maturation and for 
efficient priming, proliferation and cytokine secretion of T cells (105). LT-R triggering by 
lymphotoxins induces the classical and alternative NF-B signaling pathways which are linked to 
inflammation-induced carcinogenesis (106). The impact of the lymphotoxin signaling on tumor 
promotion still has to be defined for other tumor types. 
Recent studies have shown that certain pro-inflammatory cytokines such as IL-23, IL-17 and 
TNF-can promote tumor development and growth, since experimental tumor growth is 
decreased in the absence of such cytokines (107-109). However, also a role in enhancing anti-
tumor immunity was observed for IL-17 and it is still under debate whether Th17 cells exert more 
pro- or anti-tumorigenic functions (110). Besides its tumor-promoting role, also TNF- was shown 
to protect the host against tumor formation by being important for priming, proliferation and 
recruitment of tumor-specific T cells (111).  
 
 
1.5  Tumor-associated macrophages (TAMs) 
 
Macrophages are part of the innate immune system and play an important role in many aspects 
of immunity (112). 
Classical activation of macrophages occurs during acute inflammation and (bacterial) infections 
and is mediated by IFN- and LPS. Alternative activation frequently occurs in the context of 
chronic inflammation and is in part mediated by IL-4 and IL-13 (113-116). Because of the 
parallels in the cytokine profile of macrophages and CD4+ T cells, Mills initiated the terminology 
M1/M2 macrophages for classically activated and alternatively activated macrophages in analogy 
to the Th1/Th2 paradigm (117).  
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M1 and M2 macrophages can be distinguished based on differential expression of transcription 
factors and surface molecules, as well as due to disparities in their cytokine profile and 
metabolism. A simplified picture that compares M1 and M2 macrophages is shown in Figure I-4. 
 
 
 
Figure I-4: Differences in M1 and M2 macrophages  
Classical activation leads to the polarization of macrophages into tumoricidal M1 macrophages, 
while alternative activation leads to polarization of macrophages into tumor-promoting M2 
macrophages and M2 TAMs (modified from (95)). 
 
The classical M1 phenotype is promoted by IFN- mediated STAT-1 activation that promotes the 
expression of genes like IL-12, MHC-class II, and inducible nitric oxide synthase (iNOS) (118). 
IL-12 is a cytokine known to stimulate both the proliferation and cytotoxicity of T cells and NK 
cells (119). Besides IL-12, M1 macrophages also release large amounts of other proinflammatory 
cytokines such as IL-23 and TNF-(120). Due to iNOS expression, M1 macrophages catalyze 
the production of anti-microbial nitric oxide (NO) from L-arginine that was shown to be important 
for macrophage-mediated tumor killing (121). Recently, it was observed that activation of the 
interferon regulatory factor-5 (IRF-5) also facilitates the M1-associated phenotype, and genome-
wide expression analysis revealed that IRF-5 induces the expression of M1-signature genes and 
represses the M2-specific genes (122).  
In contrast, signaling downstream of the IL-4 receptor leads to the activation of STAT-6 (123), a 
master regulator of M2 genes such as the mannose receptor (MR) and to a reduction of iNOS 
(124). In mice, M2 macrophages express increased levels of Arginase-1, which hydrolyses L-
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Arginine into urea and L-ornithine. These products are further metabolized into polyamines and 
prolines, molecules involved in proliferation and tissue remodeling processes (125). IL-10, also 
involved in M2 polarization, induces activation of STAT-3 that leads to upregulation of SOCS3 an 
inhibitor of cytokine signaling leading to decreased secretion of Th1 type immune mediators 
thereby promoting T cell tolerance (126, 127). Recently it was shown that also IRF-4 specifically 
regulates M2-signature genes and by this M2 macrophage polarization (128).  M2 macrophages 
are known to mediate parasite clearance, suppress inflammation and support immunoregulation 
through for example the production of IL-10 and the promotion of Treg differentiation (120, 129). 
 
Tumor-associated macrophages (TAMs) originate from blood monocytes that are recruited to the 
tumor already early during tumor development by tumor-derived signals, including CSF-1 and 
VEGF (130, 131). Due to the functional plasticity of macrophages, their phenotype can be 
influenced by factors of the tumor microenvironment, such as cytokines and hypoxia. In regard of 
cytokines and chronic state, established cancer resembles the situation of chronic inflammation. 
In this line, it was shown that tumor-conditioned media, as well as TGF- and/or IL-10, major 
cytokines present in the tumor microenvironment, induce phonotypical changes in macrophages 
reminiscent of alternative activation (IL-4/IL-13) and M2 macrophages (132, 133). Such polarized 
TAMs, termed M2 TAMs hereafter, show an impaired expression of reactive nitrogen 
intermediates (NO) and high expression of angiogenic factors like VEGF and EGF (120). 
Furthermore, IL-12 is strongly reduced in M2 TAMs, while IL-10 production is markedly 
increased. While monocytes differentiated ex vivo to macrophages were able to lyse autologous 
tumor cells (134), neither macrophages from PBMCs of cancer patients (135) nor TAMs isolated 
from tumor ascites (136) showed anti-tumoricidal activity. 
Whereas the pan-macrophage marker CD68 is found on diverse subtypes of macrophages (137), 
M2 but not M1 TAMs express the hemoglobin scavenger receptor CD163 (132, 138). 
Furthermore, M2 TAMs were shown to express higher levels of MR (139) and Fibronectin 1 (FN-
1) (132, 140), and specifically express the migration-stimulating factor (MSF), a FN-1 isoform 
(132). Very recently c-MYC was identified as a marker for M2 TAMs (141). c-MYC is induced in 
human macrophages upon IL-4 and other M2-like stimuli, and is expressed in human CD68+ 
TAMs in which it controls various M2-associated and protumoral genes (141). 
M2 TAMs support the progression of cancer by many different aspects including the promotion of 
angiogenesis, matrix remodeling and metastasis (142-144). A positive paracrine feedback loop 
between tumor cells and TAMs promoting tumor cell invasiveness was shown in breast cancer 
(145). Tumor cells secrete colony stimulating factor 1 (CSF-1) and thereby recruit CSF-1 receptor 
(CSF-1R) positive TAMs to the tumor (Figure I-5). The interaction of CSF-1 and its receptor 
induces the secretion of epidermal growth factor (EGF) by TAMs that stimulates the production of 
CSF-1 by EGF receptor (EGFR) positive cancer cells. EGF promotes the formation of elongated 
protrusions and cell invasion. In humans CSF-1 not only impacts on TAMs, but also can bind to 
the CSF-1R on tumor cells and by this further amplifies the secretion of CSF-1 via an autocrine 
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loop (146). It was shown that the invasion of tumor cells can be blocked by either inhibiting the 
CSF-1R or the EGFR. Along this line, blockade of CSF-1 induced signaling reduced the number 
of macrophages in tumors and correlated with reduced mammary tumor metastasis (147). Mena, 
an actin regulatory protein, was found to be upregulated in human breast cancer as part of the 
tumor invasive signature (148). It was suggested to act downstream of the EGFR and enhances 
the sensitivity of cells towards EGF, leading to an increased metastatic potential of tumor cells 
(149). High Mena levels are associated with increased invasiveness and poor clinical outcome in 
breast cancer and melanoma patients (150, 151). Very recently it was suggested that the 
interaction of CSF-1 and CSF-1R induces M2 polarization in TAMs and that cytokines secreted 
by these TAMs activates STAT-3 in ccRCC tumor cells and consequently promotes cancer 
progression (152). 
 
 
 
Figure I-5: EGF and CSF-1 dependent macrophage-mediated promotion of tumor invasion 
A paracrine loop between macrophages, expressing CSF-1R and secreting EGF, and cancer 
cells, expressing EGFR and secreting CSF-1, leads to tumor invasion of breast cancer cells. This 
interaction is amplified by a CSF-1/CSF-1R autocrine loop of tumor cells and by Mena acting 
downstream of the EGFR (adapted from (146)). 
 
TAMs promote tumor growth also in a tumor-extrinsic fashion, namely by suppressing local 
tumor-specific immunity (115, 133, 153). It is therefore not surprising that a high frequency of 
TAMs is often associated with an unfavorable prognosis (154). However, limited data are 
available on the correlation between prognosis and macrophage phenotype in human cancer. 
Furthermore, the nature and consequences of local interactions between TAMs and other 
components within the tumor, including T cells and tumor cells, are largely unknown. 
 
 
1.6 Renal cell carcinoma  
 
Renal cell carcinoma (RCC) encompasses a heterogeneous group of cancers deriving from the 
renal parenchyma (155). The majority of renal malignancies (85-95%) are classified as RCCs 
(156), which account for 3% of all adult neoplasms (157). According to the WHO classification 
RCC is divided in three major histological subtypes: clear cell RCC (ccRCC, 80-90%), papillary 
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RCC (10-15%) and chromophobe RCC (4-5%) (158). Figure I-6 displays the macroscopic 
appearance of RCC and microscopic representations of the major subtypes.  
 
 
Figure I-6: RCC and its most common histological subtypes 
Macroscopic and microscopic representations of RCC 
(http://health.act.gov.au/health-services/canberra-hospital/our-services/act-pathology/about-act-
pathology/pathology-museum/urinary-system/left-kidney-renal-cell-carcinoma, 
http://en.wikipedia.org/wiki/Renal_cell_carcinoma). 
 
An association between subtype and survival was observed in different studies, with ccRCC 
being the most aggressive tumor followed by papillary and chromophobe RCC (159, 160). Since 
RCC subtypes represent dissimilar diseases in morphology, genetics and clinical course (161), 
we restricted our analysis to the most common subtype - ccRCC - to minimize heterogeneity and 
because most established clinical data are available for ccRCC (162). 
An elevated risk to develop RCC was observed with increased tobacco exposure, hypertension 
and obesity (163). Most RCCs are detected by chance when patients undergo medical 
examinations of the abdomen because of apparently unrelated symptoms. Less than 10% of 
RCC cases show the classic triad of symptoms that is hematuria (blood in the urine), abdominal 
or flank pain, and palpable mass on physical examination, usually a sign for a more advanced 
disease (164). The development of the clear cell subtype is closely linked to the loss of the von 
Hippel-Lindau (VHL) gene product (pVHL) and subsequent deregulation of the hypoxia inducible 
factor (HIF) family of transcription factors (165). Individuals with one defective copy of the VHL 
gene have an increased risk to develop ccRCC (166). Knockout studies, however, demonstrated 
that loss of VHL alone is not sufficient for ccRCC development and that thus additional events 
have to occur (167, 168).  
Standard treatment of local disease is surgical resection of the tumor by radical or partial 
nephrectomy. RCC is curable by this treatment when detected sufficiently early, however, about 
one-third of patients already developed metastatic disease at time of diagnosis and about one-
third develops metastases at a later time-point after surgery, which suggests the presence of 
undetected (micro)metastases at the time of surgery (169). Treatment of advanced and 
metastatic disease is challenging since RCC is highly resistant to chemo-, hormone- and 
radiotherapy (170) leading to poor prognosis for those patients with a 5-year survival rate of less 
than 10% (171).  
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Since deregulation of HIF is an important aspect of ccRCC development, agents blocking HIF 
target genes, especially vascular epithelial growth factor receptor (VEGFR) and platelet derived 
growth factor receptor (PDGFR), are currently evaluated in many clinical trials. The small 
molecule receptor-kinase inhibitors sunitinib and sorafenib, which target anti-angiogenesis, have 
been proven worldwide as second line standard treatments for metastatic RCC (172, 173). 
Clinical response was observed for sorafenib and sunitinib treatment (174, 175) however, 
complete responses were not observed after treatment with any of those inhibitors. 
It is well established that RCC is an immunogenic tumor. For example, immunosuppressed 
patients have an increased incidence of RCC (33, 176), and RCC is more heavily infiltrated by 
immune cells than other cancers (177, 178). In addition, reports of long dormancy of metastatic 
lesions (179) and observations of spontaneous regression of RCC tumors in some cases (180, 
181) support the thesis that RCC is controlled by the immune system. 
 
 
1.7 Aims of this study 
 
Basic research aimed at understanding the relations between RCC and immune cells has led to 
a complex network with many players (Figure I-7) (182, 183). 
 
 
Figure I-7: Immunoregulation in ccRCC 
Stimulatory interactions of immune cells and tumor cells are represented with +, inhibitory signals 
with -, and direct cytotoxic effects of immune cells with    . 
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To identify which immunological parameters correlate with a favorable course of ccRCC, we 
correlated their expression with the most powerful and meaningful readout in humans: survival. 
Furthermore, we evaluated whether the local and peripheral immune responses differ 
phenotypically or functionally and if so, whether the tumor microenvironment contributes to the 
differences. 
 
The specific aims of this study are 
 
1) To detect TAA-specific T cell responses in PBMCs and TILs of ccRCC patients 
2) To identify an immunological signature that correlates with patient survival 
3) To elucidate the impact of the tumor microenvironment and the identified 
immunological parameters on T cell phenotype and function 
 
For aims 1 and 3, I collected blood and fresh tumor material from 91 patients with kidney cancer, 
who underwent surgery as part of their treatment (summary Table I-1). Experiments were only 
performed on material from patients, who were newly diagnosed with the clear cell RCC subtype. 
I performed the experiments for aim 2 on formalin-fixed paraffin-embedded tumor material from 
60 patients with primary ccRCC of whom information on tumor stage (pT) and survival was 
available (Table S2 in results part 2.2). 
 
 
Table I-1: Summary of fresh patient material collected in the scope of this thesis 
all samples     
 
clear cell RCC     
  # % 
 
  pT # 
patients 91 100 
 
tumor stage (pT) 1 2 
  
 
  
 
  1a 16 
malignant samples 71 78 
 
  1b 6 
clear cell RCC 36 50.7 
 
  1c 0 
papillary RCC 13 18.31 
 
  2 4 
chromophobe RCC 9 12.68 
 
  3a 3 
mixed forms of RCC 4 5.63 
 
  3b 5 
others 6 8.45 
 
  3c 0 
distant metastases 3 4.23 
 
  4 0 
    
  
 
  
  
 
  
 
HLA-A2 positive 51.43%   
  
 
  
 
HLA-A2 negative 48.57%   
  
 
  
 
  
 
  
  
 
  
 
patient age (years) average 63 ± 10 
      
 
  range 37 - 84 
 
All patients underwent full or partial nephrectomy as part of their standard treatment at the 
Department of Urology, University Hospital Zurich, within the years 2008 to 2011. Clinical 
specimens (tumor samples and peripheral whole blood) were obtained following informed 
consent in accordance with the Declaration of Helsinki. The local ethics committee approved this 
study (EK-1017).  
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2.  RESULTS 
 
 
2.1  Spontaneous peripheral T cell response towards the tumor-associated antigen 
Cyclin D1 (CCND1) in patients with clear cell renal cell carcinoma 
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ABSTRACT 
 
Renal cell carcinoma (RCC) is a heterogeneous group of kidney cancers with clear cell RCC 
(ccRCC) as the major subgroup. We analyzed the expression and immunogenicity of different 
tumor-associated antigens (TAAs) in ccRCC patients. We found expression of MAGE-A9 and 
NY-ESO-1 and overexpression of PRAME, RAGE-1, G250, Cyclin D1, ADFP, C-MET and RGS-5 
in many of the 23 primary ccRCC tumor samples tested. Subsequently, we investigated the 
presence of CD8+ T cells specific for previously identified HLA-A2-restricted peptides derived 
from the relevant TAAs in the blood of HLA-A2+ patients. We found spontaneous responses 
towards Cyclin D1 in 5 out of 6 patients with Cyclin D1-positive tumors. Cyclin D1-specific CD8+ 
T cells secreted TNF-, IFN-, and IL-2 and degranulated, suggesting the presence of 
polyfunctional tumor-specific CD8+ T cells in the blood of patients with primary ccRCC. 
The frequent occurrence of Cyclin D1 overexpression in ccRCC specimens (43%) and the 
frequent detection of functional Cyclin D1-specific T cells in those patients (83%) makes Cyclin 
D1 an interesting target for future immunotherapeutic strategies. 
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INTRODUCTION 
 
The immune system recognizes and controls tumors through a process called cancer immune 
surveillance (1). In support of this, several studies found a correlation between the degree of 
tumor infiltration by T cells and survival in different cancer entities (2). In addition, spontaneous 
tumor-specific immunity can be detected in cancer patients (3), which is targeted to tumor-
associated antigens (TAAs). TAAs include cancer-testis (CT) antigens, differentiation antigens, 
mutated proteins, overexpressed proteins and viral antigens (4). Boosting spontaneous TAA-
specific immunity in cancer patients is a strategy with low toxicity, which resulted in objective 
clinical responses in some patients (5).  
Renal cell carcinoma is a heterogeneous group of tumors that encompasses about 90% of all 
human kidney tumors, with ccRCC as the major histological subgroup (6). If detected early, 
patients can be cured by resection; however, about one-third of the tumors already metastasized 
at the time of diagnosis. Moreover, about 20-50% of patients will develop metastasis despite 
resection (7). Treatment of advanced and metastatic disease is challenging due to the relative 
chemo- and radiotherapy resistance of RCC (8). 
Spontaneous regressions and the increased incidence of RCC in immunosuppressed patients, 
as well as the high density of tumor-infiltrating leukocytes (TILs) suggest immune recognition of 
this tumor type (9). For this reason, RCC patients are being treated with immunostimulatory 
compounds including IL-2 and/or IFN- since the 1980s. Despite modest therapeutic efficacy 
observed in some patients, concomitant severe systemic toxicity is a problem (8). Although RCC 
is generally considered as an immunogenic cancer, data showing TAA-specific immunity in RCC 
patients are scarce.  
We investigated tumor samples of 23 patients with primary ccRCC for the expression of genes 
encoding the CT antigens MAGE -A1 (CT1.1), -A3 (CT1.3), -A4 (CT1.4), -A9 (CT1.9), -A10 
(CT1.10), synovial sarcoma X breakpoint 2 (SSX2/CT5.2), New York esophageal I (NY-ESO-
1/CT6.1), L antigen 1 (LAGE-1/CT6.2) and MAGE-C1 (CT7), carbonic anhydrase IX (CA-
IX/G250), renal antigen 1 (RAGE-1), preferentially expressed antigen of melanoma (PRAME), 
adipose differentiation-related protein (adipophilin/ADFP), C-MET proto-oncogene, Cyclin D1 
(CCND1), and regulator of G-protein signaling 5 (RGS-5) via qRT-PCR. Furthermore, we 
investigated whether any of these antigens had induced spontaneous T cell responses in 
patients with primary diagnosed ccRCC. 
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RESULTS 
 
Frequent expression of tumor-associated antigens in primary ccRCC tumor samples 
We investigated the expression of 9 CT antigens and 7 additional antigens in 23 primary ccRCC 
specimens by qRT-PCR. We found expression of MAGE-A9 in 36% and of NY-ESO-1 in 55% of 
the samples, whereas the other 7 CT antigens were not expressed (Figure 1A). Although 
MAGE-A9 and NY-ESO-1 were frequently expressed, their expression levels were very low 
(Figure 1B). Furthermore, we observed overexpression of RAGE-1 in 13%, C-MET in 30%, 
PRAME in 39%, Cyclin D1 in 43%, ADFP in 65%, RGS-5 in 83% and CA-IX in 96% of ccRCCs 
(Figure 1A, B). More than 50% of the ccRCCs co-expressed 4-6 different TAAs (Figure 1C). We 
observed no evidence for preferred co-expression of particular TAAs (Figure 1D). 
 
Spontaneous Cyclin D1-specific CD8+ T cell responses in patients with primary ccRCC 
Because limited material availability precluded the use of overlapping peptides derived from all 
overexpressed TAAs, we selected HLA-A2+ patients and used previously described HLA-A2 
restricted peptides for stimulation of PBMC (http://www.cancerimmunity.org/CTdatabase, (10-12), 
summarized in Table 2). After in vitro restimulation for 9 days with the relevant peptides, we 
performed a 5 h restimulation with the same peptides in the presence of brefeldin A and 
monensin, followed by intracellular staining (ICS) for the effector cytokines TNF-, IFN- and IL-2 
as well as staining for degranulation (surface CD107a). We found CD8+ T cells specific for Cyclin 
D1-derived peptides in 5 out of 6 HLA-A2+ patients, whose tumors overexpressed Cyclin D1 
(Figure 2A), but not for any of the other peptides tested (data not shown). Due to limited 
material, the readout for patients Z-H-1144, Z-H-209, Z-H-929 and Z-H-1055 was performed with 
both Cyclin D1-derived peptides (Cyclin D1101-109 and Cyclin D1228-236) together. From patient Z-H-
1184 and Z-H-1257, however, enough material was available for separate analysis of both Cyclin 
D1-derived epitopes and we found that the response in both patients was directed against Cyclin 
D1101-109 as illustrated by a representative staining of patient Z-H-1184 (Figure 2B). Furthermore, 
the Cyclin D1-specific CD8+ T cell response in all 5 patients had a polyfunctional character 
although only few cells secreted IL2 (Figure 2C). 
To confirm the presence of Cyclin D1-specific T cells in ccRCC patients we additionally 
performed ex-vivo tetramer staining on PBMCs (Supplementary Figure S1A) and TILs 
(Supplementary Figure S1B) of ccRCC patients, when sufficient material was available. In 
PBMCs of patient Z-H-209, who did not show a Cyclin D1-specific response after in vitro 
stimulation, we also did not detect any tetramer-positive T cells. However, in the other patients 
tested, who responded to in vitro Cyclin D1-specific peptide stimulation (Z-H-903, Z-H-1055 and 
Z-H-1184), we detected Cyclin D1-specific T cells in PBMCs ex vivo by tetramer staining 
(Supplementary Figure S1A). While we could not find Cyclin D1-specific T cells in TILs of 
patient Z-H-929, whose PBMCs only responded weakly towards in vitro Cyclin D1-specific 
peptide stimulation, we detected tetramer-specific T cells in TILs of patient Z-H-1184 and Z-H-
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1257, whose PBMCs clearly responded with cytokine secretion towards peptide stimulation 
(Supplementary Figure S1B). 
To investigate whether Cyclin D1 induces a humoral immune response in ccRCC patients, we 
tested for Cyclin-D1 specific antibodies by Western blotting, however, we did not observe 
antibodies in serum of any of the 22 patients tested (Supplementary Figure S2). 
 
 
DISCUSSION 
 
To expand the number of clinically relevant TAAs that can be targeted by immunotherapy in 
patients with RCC, we investigated the expression of several CT antigens and some 
overexpressed antigens (13), in a panel of 23 primary ccRCC samples. We observed that most 
tumors expressed more than one TAA, which has been described for other tumor entities as well 
(14-16) and which enables therapeutic targeting of multiple antigens at the same time. 
Except for MAGE-A9 and NY-ESO-1, we did not detect expression of any of the CT antigens 
analyzed in our patient cohort. Although some studies showed expression for MAGE-A3 and -A4 
in RCC (17, 18) our results are in line with those of a previous review on CT antigens (19). The 
expression frequency of MAGE-A9 is in accordance with a previous study (10), however, we 
observed only very low levels of MAGE-A9 transcripts. Furthermore, as reported before (10), we 
also detected a signal for MAGE-A9 in the healthy kidney tissue control. The frequent expression 
of NY-ESO-1 was unexpected and is in discrepancy with published data (20-22). Using a highly 
sensitive qRT-PCR method we detected very low levels of NY-ESO-1, which may explain the 
discrepancy to other studies that mainly used immunohistochemistry. Although RAGE-1 was the 
first antigen recognized by autologous T cells on a human RCC cell line, it was only detected it in 
1 out of 57 RCC samples (23). Our results are in agreement with other studies that observed 
higher expression frequencies, presumably due to more sensitive methods (10, 20). Furthermore, 
the frequency of PRAME-expression in ccRCC found here is in accordance with previously 
published reports (18, 20).  
The von Hippel-Lindau protein (VHL) is mutated in most of ccRCC samples leading to a reduced 
proteolytic degradation of hypoxia inducible factor  (HIF-) and as a result to upregulated HIF-
-mediated transcriptional programs (24). CA-IX is one of the HIF- target genes that is 
frequently expressed in RCC but very rarely detected in normal kidney tissue (25). We observed 
an overexpression of CA-IX in all samples but one. CA-IX was described as a useful therapeutic 
target for RCC (11, 26, 27), which was evaluated in different clinical studies (28-30), but was so 
far not proven to induce a strong anti-tumor immune response. Besides CA-IX, ADFP, Cyclin D1, 
C-MET and RGS-5 are overexpressed in ccRCC (12). We found that ADFP was expressed more 
frequently than C-MET which is in contrast with published data (31, 32).  Cyclin D1 is a cell cycle 
regulator that is crucial for G1-S transition (33) and is overexpressed in many cancers including 
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colorectal and breast carcinoma (34, 35). We found an overexpression in 43% of primary ccRCC 
samples, which is in the range of previously published data (36-38).   
Although expression is a prerequisite for targeting, the amount of antigen, its expression pattern 
(homo- vs. heterogeneous) and its immunogenicity impact on the success of immunotherapy 
(20). Indeed, despite the frequent expression of NY-ESO-1, which is one of the most 
immunogenic CT antigens (22, 39) we did not find NY-ESO-1-specific CD8+ T cell responses in 
any of the HLA-A2+ ccRCC patients. We explain this finding by the low level of NY-ESO-1 
expression. ADFP, C-MET and RSG-5 presumably are not very immunogenic in ccRCC patients, 
because we did not detect specific T cell responses towards these antigens, despite their 
frequent overexpression. This is in agreement with previously published data that described rare 
T cell responses in ccRCC patients (13), despite the fact that ADFP- and C-MET-specific T cells 
could be expanded from the blood of healthy donors (31, 32). We found no specific T cells to 
either of those antigens. Also RGS-5 overexpression did not result in detectable T cell responses 
in our cohort, although such responses were reported in blood of healthy donors and patients 
with acute myeloid leukemia (40). 
In contrast, we detected Cyclin D1-specific CD8+ T cells in the blood of 5/6 HLA-A2+ patients, 
who overexpressed Cyclin D1 in the tumor, suggesting that overexpressed Cyclin D1 is 
immunogenic in patients with ccRCC. To test whether these T cell responses are directed 
towards a mutated epitope of Cyclin D1 in ccRCC, as observed before for the cyclin-dependent 
kinase 4 (CDK4) in melanoma (41), we sequenced the two Cyclin D1 epitopes. However, 
mutations of Cyclin D1 are very unlikely (42) and also here we did not find evidence for mutation 
(data not shown).  
Ex vivo tetramer staining confirmed the presence of Cyclin D1-specific T cells in those patients 
who responded with cytokine secretion towards in vitro Cyclin D1-specific peptide stimulation. 
Although we detected a higher frequency of T cells specific for Cyclin D1228-236 by tetramer in 
blood and TILs, we found a higher frequency of T cells specific for Cyclin D1101-109 after in vitro 
restimulation followed by ICS. This observation may be explained by the possibility that Cyclin 
D1228-236 is the immunodominant peptide and resulting in a more extensive in vivo proliferation of 
specific T cells, which may have compromised their ability to further expand in vitro. Alternatively, 
but not mutually exclusive, tetramer-positive T cells must not necessarily be functional, which 
may suggest a preferential functional exhaustion of T cells specific for Cyclin D1228-236.  
While in the case of ccRCC no association between Cyclin D1 expression and prognosis was 
observed (38) in most other cancers Cyclin D1 overexpression is associated with shorter patient 
survival and represents an interesting therapeutic target (42). However, since Cyclin D1 is 
intracellularly expressed and lacks intrinsic enzymatic activity it is difficult to target. One approach 
is to block the activity of Cyclin D1 indirectly by inhibiting associated kinases by specific kinase 
inhibitors (43), however, this strategy does not interfere with its kinase-independent tumor 
promoting effects.  
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Cyclin D1 induces immune responses in a variety of other cancers. For example Cyclin D1-
specific CD4+ and CD8+ T cells can be expanded by prolonged in vitro restimulation from blood 
of healthy donors and patients with mantle cell lymphoma or colon cancer (44-46). Along this 
line, Cyclin D1 was identified before as a target for immunotherapy in mantel cell lymphoma (47). 
Whereas we did not find antibodies against Cyclin D1 in sera of ccRCC patients, such antibodies 
were detected in patients with prostate cancer (48).  
To our knowledge this is the first study that describes naturally occurring Cyclin D1-specific CD8+ 
T cell responses in cancer patients. Importantly, these responses had a polyfunctional effector 
character. We therefore propose Cyclin D1 as a target for immunotherapy in patients with 
ccRCC. 
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FIGURES AND TABLES 
 
Table 1: Patient information 
          
Histology 
 
clear cell renal cell carcinoma 
  
   
  
Patient number n=23 
 
  
  
   
  
Age (years) 
 
37-84 (64.1 ± 11)   
  
   
  
Pathological Stage pT1 1   
  
 
pT1a 8   
  
 
pT1b 4   
  
 
pT2 3   
  
 
pT3 0   
  
 
pT3a 3   
  
 
pT3b 4   
  
 
pT3c 0   
  
 
pT4 0   
          
 
 
 
Table 2: Taq-Man Assays of TAAs and derived HLA-A2 restricted peptides 
  TaqMan Assay ID Position Peptide Sequence Peptide Source 
MAGE-A1 Hs00607097_m1 278-286 KVLEYVIKV not used 
MAGE-A3 Hs00366532_m1 271-279 FLWGPRALVd not used 
MAGE-A4 Hs00365979_m1 230-239 GVYDGREHTV not used 
MAGE-A9 Hs00893224_m1 223-231 ALSVMGVYV Thermo Scientific 
MAGE-A10 Hs01560792_m1 254-262 GLYDGMEHL not used 
SSX2 Hs00817683_m1 41-49 KASEKIFYV not used 
NY-ESO-1 Hs00265824_m1 157-165 SLLMWITQC Bio Synthesis 
LAGE-1 Hs00535628_m1 41214 MLMAQEALAFL not used 
    157-165 SLLMWITQV not used 
MAGE-C1 Hs00193821_m1 959–968  ILFGISLREV not used 
    1083–1091  KVVEFLAML not used 
PRAME Hs00196132_m1 425-433 SLLQHLIGL Thermo Scientific 
    100-108 VLDGLDVLL Thermo Scientific 
RAGE-1 Hs00179504_m1 32-40 PLPPARNGGL Thermo Scientific 
    352-360 LKLSGVVRL Thermo Scientific 
CA-IX Hs00154208_m1 254-262 HLSTAFARV Thermo Scientific 
CCND1 Hs00765553_m1 101-109 LLGATCMFV  S. Stefanovic, Tuebingen 
    228-236 RLTRFLSRV  S. Stefanovic, Tuebingen 
ADFP Hs00765634_m1 129-137 SVASTITGV  S. Stefanovic, Tuebingen 
C-MET Hs00179845_m1 654-662 YVDPVITSI  S. Stefanovic, Tuebingen 
RGS-5 Hs00186212_m1 5-13 LAALPHSCL  S. Stefanovic, Tuebingen 
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Figure 1: Expression of TAA transcripts in ccRCC specimens 
RNA was isolated from 23 primary ccRCC samples, reverse transcribed and used as template for 
qRT-PCR analysis. (A) Frequency of expressed TAAs in primary ccRCC samples. (B) Detected 
CT levels for the different TAA transcripts of the individual tumor samples after normalization to 
the endogenous control (18S rRNA). Results from tumor samples are represented as open, from 
testis as filled, and from healthy kidney as half-filled symbols. (C, D) Co-expression of TAAs in 
primary ccRCC samples.  
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Figure 2: Cyclin D1-specific CD8+ T cell response in PBMCs of ccRCC patients 
CD8+ T cells from PBMCs of HLA-A2+ patients with Cyclin D1-overexpressing tumors were 
stimulated for 9 days with Cyclin D1-derived peptides in the presence of IL-2. Restimulation was 
performed using both Cyclin D1-derived epitopes (Cyclin D1101-109 and Cyclin D1228-236) together, 
separately or no peptide as highlighted in the figure, followed by surface staining for CD107a and 
intracellular staining for TNF-, IFN- and IL-2. Cytokine production of CD8+ T cells was 
measured after gating on live CD45+, CD3+, CD8+, CD14-, CD16-, CD19- cells. (A) Summary of 
results from 6 individual patients. (B) Representative staining (patient P5) of single cytokine 
secretion. (C) Polyfunctional cytokine response. 
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SUPPLEMENTARY FIGURES 
 
 
A CCND1101-109 CCND1228-236 FLU-M58-66
Z-H-903
Z-H-209
CD8
te
tr
a
m
e
r
Z-H-1184
Z-H-1055
RESULTS 
34 
 
 
Supplementary Figure S1: Cyclin D1-specific tetramer staining in PBMCs and TILs of ccRCC 
patients  
 
PBMCs (A) and TILs (B) were incubated with PE-conjugated Cyclin D1-specific tetramers and as 
a control with FLU-specific tetramers for 10 minutes at 37 °C, followed by incubation with CD45 
APC, CD8 PasificBlue and live-dead stain (LIVE/DEAD® Fixable Aqua Dead Cell Stain Kit, 
Invitrogen) for 15 minutes at 4°C. Samples were measured with a CyAn ADP 9 (Beckman 
Coulter) and data were analyzed using the FlowJo software (TreeStar). Dot plots are shown after 
gating on live (aqua-) single CD45+ cells.  
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Supplementary Figure S2: Imunoblotting for Cyclin D1 in sera of ccRCC patients  
Serum antibody response against the purified recombinant protein was tested by standard 
Western blot analysis using 3.6 mg of recombinant human Cyclin D1 (Abnova Cat.No. 
H00000595-PO1) and sera from 22 ccRCC patients at a 1:250 dilution. As positive control, 
purified MaxPab mouse polyclonal antibody anti-human CCND1 (Abnova Cat.No. H00000595-
BO1P) was used at a 1:1000 dilution. As secondary reagents HRP-conjugated goat anti-mouse 
IgG (Jackson 115-035-008) was used for the positive control and HRP-conjugated goat anti-
human IgG (Jackson 109-035-006) for the sera, both at a dilution of 1:25 000. Detection was 
done with Western Lightning Plus ECL reagents (Perkin Elmer Cat.No. NEL104001EA) on a 
Fusion FX7 machine (VILBER LOURMAT).  
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MATERIALS AND METHODS 
 
Patients 
Patients with ccRCC underwent full or partial nephrectomy as part of their standard treatment at 
the Department of Urology, University Hospital Zurich, within the years 2008 to 2011. Clinical 
specimens (tumor and peripheral whole blood) were obtained following informed consent in 
accordance with the Declaration of Helsinki. The local ethics committee approved the study (EK-
1017, EK-1634). Detailed patients’ characteristics are listed in Table 1. All patients were typed 
for HLA-A2 by flow cytometry using FITC-conjugated HLA-A2-specific or isotype control 
antibodies (BioLegend). Flow cytometry was performed on a CyAn ADP 9 (Beckman Coulter) 
and data were analyzed using the FlowJo software (TreeStar).  
 
Processing of blood and tumor samples 
PBMCs were isolated from peripheral blood by Ficoll (Ficoll-PaqueTM PLUS; GE Healthcare) 
density centrifugation and cryopreserved at -80°C until further analysis. Immediately after surgery 
one tumor tissue sample was snap-frozen in liquid nitrogen and another one was fixed in 4% 
buffered formalin and embedded in paraffin. 
 
RNA isolation 
Total RNA was extracted from snap-frozen ccRCC tumor samples using the RNeasy Mini Kit 
(Qiagen) and was subsequently digested with DNAse I (New England BioLabs) according to the 
manufacturer’s instructions. 
 
Real-time quantitative reverse transcription–polymerase chain reaction (qRT-PCR) 
The concentration and purity of RNA was evaluated using the NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies). Five hundred ng of RNA was reverse transcribed 
using the high-capacity cDNA Reverse Transcription Kit (Applied Biosystems) according to the 
manufacturer’s instructions. The obtained cDNA was stored at -20 °C until qRT-PCR analysis. 
qRT-PCR was performed on a Rotor-Gene Q real-time PCR cycler (Qiagen) using commercially 
available predeveloped TaqMan reagents with optimized primer and probe concentrations 
(TaqMan® gene expression assays, Applied Biosystems) (Table 2). After an initial hold for 2 min 
at 50 °C and 10 min at 95 °C the probes were cycled 45 times at 95 °C for 15 sec and at 60 °C 
for 60 sec. All PCR reactions were performed in triplicates. Threshold cycle (CT) values were 
determined with the Rotor-Gene Q Series software 1.7. Ct values were calculated by 
normalizing the target mRNA levels to the endogenous control 18s-rRNA (Hs03928990_g1, 
Applied Biosystems). Testis cDNA served as a positive control for the expression analysis of CT 
antigens (human testes total RNA, Invitrogen). As qRT-PCR for MAGE-A9 suggested a low 
expression in the healthy kidney control (CT 35, CT 30), expression in ccRCC specimens was 
only regarded positive at a CT < 35 and a Ct < 30. In the case of overexpressed antigens Ct 
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levels of tumors were compared to Ct levels of the healthy kidney control (human kidney total 
RNA, Invitrogen) using the 2-Ct formula. Only changes ≥2 fold were considered as 
overexpression.  
 
Genomic DNA extraction 
Punch biopsies from paraffin-embedded ccRCC samples were incubated 10 min at 95 ºC with 
300 μL of buffer containing 20 mM Tris pH 8.0, 20 mM EDTA pH 8.0 and 1% SDS. After cooling 
down, 3 μL of Proteinase K (18 +/- 4 mg/mL, Roche) were added to each sample and incubated 
at 55 ºC for 72 hours. Digested samples were centrifuged and 4 volumes of RLT buffer (AllPrep 
DNA/RNA Mini Kit, Qiagen) was added to the supernatant. Genomic DNA was then extracted 
following manufacturer’s protocol.  
 
Cyclin D1 sequencing 
PCR amplification using purified genomic DNA was performed using the Phusion Hot Start High-
Fidelity DNA Polymerase (Finnzymes) with the following PCR conditions: 10 min at 98 °C, 
followed by 34 cycles of 30 sec at 98 ºC, 30 sec at 68 ºC, 20 sec at 72 ºC with a final elongation 
of 5 min at 72 ºC. The sequences coding for the HLA-A2-restricted CTL epitope corresponding to 
Cyclin D1 amino acids 101-109 or 228-236 were amplified using forward primer 5’-
TGCGAGGAACAGAAGTGCGA-3’ / reverse primer 5’-TCCAGTGGTTACCAGCAGCTC-3’ or 
forward primer 5’-TGCTCACAGCCTCCTTCCCT-3’ / reverse primer 5’-
TCGGCATTTCCGTGGCACTA-3’ respectively. PCR products were purified using QIAquick Gel 
Extraction Kit (Qiagen) and sequenced using the same primers as those used for the 
amplification. 
 
MACS sorting and in vitro stimulation 
T cell stimulation was performed as previously described (49). Briefly, CD8+ and CD4+ T cells 
were sequentially isolated from PBMCs by positive selection using the MACS system (Miltenyi 
Biotech) according to manufacturer’s instructions. The remaining CD8-CD4-fraction was used as 
antigen presenting cells (APCs). APCs were loaded with relevant peptides at a concentration of 
10-5 M for each peptide (Table 2). For in vitro stimulation 5 × 105 CD8+ T cells were incubated 
with 5 × 105 loaded and irradiated (30 Gy) APCs in 96-well flatbottom plates. Cellswere cultured 
for 9 days in 200 μL TC-RPMI (i.e. RPMI (Gibco), supplemented with NaHCO3 (2 g/L, Sigma), L-
glutamine (2 mM, Sigma), penicillin and streptomycin (50 U/mL, Gibco), MEM nonessential 
amino acids (1X, Gibco), sodiumpyruvate (1 mM, Gibco), 10−4 M β-mercaptoethanol (Sigma) and 
10% pooled human serum) plus DNaseI (6 U/mL, Sigma)).  T-APCs were generated from purified 
autologous CD4+ T cells by stimulation with 1 μg/mL phytohemagglutinin (PHA, Sigma) and 100 
U/mL recombinant IL-2 (R&D Systems) during 9 days. T-APCs were used as APCs during the 
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short in vitro stimulation before intracellular cytokine staining. Media was exchanged every 
second day by TC-RPMI containing 25 U/mL IL-2. 
 
Intracellular cytokine staining (ICS) 
The presence of TAA-specific T cells was tested by short-term restimulation with the relevant 
peptides, followed by intracellular cytokine staining. Briefly, T cells were stimulated with peptide-
loaded autologous T-APCs at a 1:2 ratio for 5 h in the presence of Brefeldin A (10 µg/mL, 
Sigma), monensin (10 µg/mL, Sigma), 1 g/mL anti-CD28/49d (BD) and appropriately diluted 
phycoerythrin (PE)-labeled anti-CD107a antibody. Before addition to the assay T-APCs were 
labeled with 2 µM carboxyfluorescein succinimidyl ester (CFSE, Sigma), which allowed their 
exclusion before analysis. Surface staining for CD45-PerCP, CD3-PacificOrange (Invitrogen), 
CD8-ECD (Beckman Coulter), CD14-FITC, CD16-FITC, CD19-FITC, and live-dead staining 
(LIVE/DEAD® Fixable Green Dead Cell Stain Kit, Invitrogen) was performed in PBS (NaCl 
(136mM, Fluka), Na2HPO4 (8mM, Roth), KH2PO4 (1.5mM, Roth), pH7) for 20 min at room 
temperature. Subsequently, cells were fixed with 4% formalin (Kantonsapotheke Zurich) and 
incubated for 5 min at RT with permeabilization buffer (PB: PBS supplemented with 2mM EDTA 
(Sigma), 2% FCS (PAA Laboratories), 0.05% NaN3 (Sigma) and 0.1% Saponin (Sigma)). 
Intracellular staining was performed using IFN-APC, TNF-PECy7 (ebiosciences) and IL2-
PacificBlue antibodies in PB for 20 min at room temperature in the dark. Cells were washed once 
with PB and resuspended in PBS containing 1% formalin. Samples were measured with a CyAn 
ADP 9 (Beckman Coulter) and data were analyzed using the FlowJo software (TreeStar). Unless 
stated differently, all antibodies were purchased from BioLegend. 
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ABSTRACT 
 
Malignant cells are recognized and controlled by the immune system, however, in patients with 
clinically apparent cancer immune surveillance failed. To better understand local 
immunoregulatory processes that impact on disease progression, we correlated intratumoral 
immunological profiles with survival in patients with primary clear cell renal cell carcinoma 
(ccRCC). A retrospective analysis of 54 primary ccRCCs for 31 different immune response-
related transcripts, revealed a negative correlation of CD68 (tumor-associated macrophages, 
TAMs) and FoxP3 (regulatory T cells, Tregs) with survival. Subsequent analysis for 12 TAM-
related transcripts showed an association of the M2-signature genes CD163, IRF-4 and FN-1 
with reduced survival and increased tumor stage, whereas the opposite was the case for the M1-
associated gene iNOS. 
The M2-signature of TAMs (CD68+) was found to be associated with CD163 expression as 
determined in prospectively collected fresh ccRCC tissue samples. Upon coculture with 
autologous tumor cells CD11b+ cells isolated from paired blood samples expressed CD163 and 
other M2-associated genes, suggesting that the tumor promotes the accumulation of M2 TAMs. 
Furthermore, the tumor-associated milieu as well as sorted TAMs induced skewing of 
autologous, blood-derived CD4+ T cells towards a more regulated phenotype as shown by 
decreased production of effector cytokines, increased production of IL-10 and enhanced 
expression of the co-inhibitory molecules PD-1 and Tim-3. 
Together, our data suggest that ccRCC progressively attracts macrophages and induces their 
skewing into M2 TAMs that subvert tumor-infiltrating T cells such that regulating functions are 
increased at the expense of effector functions. 
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INTRODUCTION 
 
It is well established that the immune system recognizes and can destroy tumor cells and the 
association between immune infiltration and patient prognosis was described in many different 
cancers (1). However, the interactions between immune cells and tumor cells are complex and 
we are only beginning to understand them. According to the current view, cancer and immune 
cells mutually influence each other, ultimately resulting in escape from immunological control in 
patients with overt cancer (2). Besides tumor cell-intrinsic escape mechanisms including 
downregulation of MHC molecules and/or tumor-associated antigens (TAAs), tumors can create 
an environment, which interferes with immune effector mechanisms. This includes 
immunosuppressive cytokines such as IL-10 and TGF-(3, 4) and the generation and 
recruitment of immunoregulatory cell types such as regulatory T cells (Tregs) and tumor-
associated macrophages (TAMs) including myeloid derived suppressor cells (MDSC) (5-7). 
CD68 is expressed by macrophages and there is evidence from preclinical models that TAMs are 
tumor-promoting by stimulating angiogenesis, tumor cell proliferation and metastasis, but also 
because they contribute to subversion of adaptive immune responses (8). TAMs show a 
remarkable degree of plasticity and it was shown that the conversion of proinflammatory M1 
macrophages to so-called alternatively activated M2 macrophages (9) or the preferential 
accumulation (10) of the latter subtype in tumors is crucial for their tumor-promoting effect. M1 
macrophages express the transcription factor IRF-5 (11) and are thought to exert anti-tumoricidal 
activities because of an IL-12high IL-10low phenotype (5) and high expression of inducible nitric 
oxide synthetase (iNOS) (12), which results in increased production of NO. M2 macrophages 
express the transcription factor IRF4 (13) and are characterized by an IL12low IL10high phenotype 
(5), the expression of the scavenger receptor CD163 (14), the mannose receptor (MR) (15), and 
increased levels of fibronectin 1 (FN-1) (16).  
The clinical outcome of renal cell cancer (RCC) varies considerably, especially in tumors 
presenting without metastases. The prognosis for localized disease is good with a five-year 
survival rate of more than 90% after removing the tumor via radical or partial nephrectomy (17). 
However, due to the lack of symptoms, about one-third present metastatic disease at time of 
diagnosis, and 25-50% of patients treated for local disease will develop metastasis (18). In the 
case of metastatic RCC the survival rate drops dramatically with a five-year survival rate of less 
than 15%. Treatment is difficult due to resistance to radio- and chemotherapy (19). 
RCCs are considered immunogenic tumors that are frequently infiltrated by immune cells (20). In 
contrast to breast and bladder and other cancers (reviewed in(1)), a high number of tumor 
infiltrating leukocytes (TILs) is associated with poor prognosis in RCC (21). To better understand 
the local mechanisms that preclude immunological control of clinically apparent RCC, we 
correlated intratumoral immunological profiles with survival and tumor stage (pT) in patients with 
primary clear cell renal cell carcinoma (ccRCC), which is the most frequent subtype of RCC. 
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Furthermore, we investigated the impact of the tumor microenvironment on T cell phenotype and 
function. 
 
 
RESULTS 
 
Correlation between the expression of immune response-related transcripts and survival 
in ccRCC 
To better understand the local mechanisms that preclude immunological control of clinically 
apparent RCC, we correlated intratumoral immunological profiles with survival in 54 patients with 
primary ccRCC, We retrospectively analyzed the expression of 31 immune response-related 
transcripts (Supplementary Table S1A) by qRT-PCR analysis using a collection of formalin-
fixed paraffin-embedded (FFPE) tumor tissue of ccRCC patients with known tumor size and 
course of disease. Samples of patients, who died of tumor-unrelated causes, were excluded from 
the analysis (Supplementary Table S2). We found no significant correlation using the Cox 
proportional hazard model between the degree of leukocyte infiltration (Ct values of CD45 
normalized to 18S rRNA) and survival (Fig. 1A).  
Subsequently, we determined transcripts for immune response-related genes after normalization 
to CD45, which enables the analysis of the infiltrate quality independent of the degree of 
infiltration. We correlated each of the 33 transcripts with survival using Cox regression analysis 
and present these data in Fig. 1A and Supplementary Fig. S1. We excluded the data for LT-, 
Arginase 1, BTLA, IL-2 and IL-17 from the analysis because of very low or undetectable 
expression. Univariate Cox regression analysis revealed a significant correlation of high FoxP3 
(Treg) mRNA and of high CD68 (macrophages) mRNA with reduced survival, whereas CD3 
transcripts (T cells) did not correlate with patient survival (Fig. 1A). We correlated the expression 
of CD68 transcripts with CD3, CD4 and CD8 transcripts and found no correlation between 
CD68/CD3 (correlation coefficient -0.082, two-tailed p=0.556) or CD68/CD8 (correlation 
coefficient -0.031, two-tailed p=0.882), but a significant correlation between CD68/CD4 
(correlation coefficient 0.391, two-tailed p=0.003). The latter correlation is a positive one, which 
presumably reflects the co-existence of macrophages and regulatory T cells. Furthermore, high 
expression levels of perforin and TNF- showed a correlation with increased survival, while high 
expression levels of LT-R showed a correlation with reduced survival (Supplementary Fig. 
S1A). Since, significance for these 3 genes was only achieved with one of the statistical tests 
and clearly not with the other test, these genes were not considered to significantly correlate with 
survival. In the case of CTLA-4 and IL-10 in a few samples no signal was observed, and an 
estimated value (Ct=40) was set for these samples (Supplementary Fig. S1A). When those “no-
signal” samples were excluded from the analysis, high expression values of CTLA-4 and IL-10 
significantly correlated with reduced survival (Supplementary Fig. S1B). Also for other genes 
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(marked with an asterisk Supplementary Fig. S1A) no signal was detected in a few samples, 
however statistical analysis did not reveal different results when “no-signal” samples were 
excluded (data not shown). 
While correlation of FoxP3 expression and survival just reached the level of significance using 
univariate Cox regression analysis, the correlation between CD68 mRNA levels and reduced 
survival was independent of tumor size and patients’ age as assessed by multivariate Cox 
regression analysis (Fig.1 legend). To validate the qRT-PCR results, we performed 
immunohistochemical staining for CD68 on seven ccRCC tumor samples and found a clear 
correlation between CD68 expression measured by qRT-PCR and immunohistochemistry in all 
seven samples (four examples shown in Supplementary Fig. S2).  
 
The expression of M2-associated transcripts correlates with reduced survival in ccRCC 
To further investigate the phenotype and impact of TAMs on patient survival, we analyzed the 
same samples (Supplementary Table S2) for another 12 TAM-associated genes 
(Supplementary Table S1B and Figure S1C). We found a significant correlation between low 
iNOS transcripts and decreased survival and a similar trend for high CD163 transcripts and 
decreased survival (Fig. 1B). Multivariate Cox regression analysis revealed that both correlations 
are independent of pT and patients’ age (Fig.1 legend). Along the same line, high expression of 
the M2-associated genes FN-1 and IRF-4 showed a tendency to correlate with reduced survival 
(Fig. 1B). Furthermore, we observed a positive correlation between transcripts of CD163 and the 
M2-associated genes MR, IL-10 and FN-1 as well as a negative correlation between CD163 and 
the M1 marker iNOS (Fig. 1C) suggesting that TAMs with an M2-like signature impact on 
reduced survival of patients with ccRCC.  
 
CD163high tumor-associated macrophages (TAMs) have an M2-phenotype  
We further characterized TAMs by flowcytometry in 12 fresh primary ccRCC tumor tissue 
samples. Tumors from most patients contained a subpopulation of CD45+CD3-CD19-
CD68+CD11b+CD163high cells (termed T2 population hereafter), which was absent in matched 
blood samples. In blood as well as in tumors we found a P1 and T1 population, respectively, both 
of which were characterized as CD45+CD3-CD19-CD68+CD11b+CD163low (Fig. 2A). Both T1 and 
T2 TAMs expressed higher levels of MHC class II than P1 cells, suggesting that TAMs are 
activated (Fig. 2B, Supplementary Fig. S4). Based on the high expression of CD163 and the 
mannose receptor (MR), the T2 population classifies as M2 TAMs. Furthermore, the T2 but not 
the T1 or P1 population showed increased expression of the programmed death ligand 1 (PD-L1) 
(Fig. 2B and Supplementary Fig. S4). To further strengthen the presumption that CD163 
associates with M2 TAMs, we performed qRT-PCR analysis on sorted T2 TAMs for different M1- 
and M2-related genes (Supplementary Table S1B and parts of S1A). When we compared T2 
and P1 cells for expression of M2-associated genes, we found a strong increase of FN-1 and IL-
10 and even a slight increase of IRF-4 and the transcription factor c-MYC(22) in the T2 
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population, whereas the expression of the M1-associated genes IRF-5, iNOS and IL-12 was low 
(Fig. 2C). Except for elevated expression of CD163 and MR, no clear differences of M1 and M2 
genes were observed in T2 compared to T1 population on the mRNA level (Supplementary Fig. 
S5). 
 
The expression of M2-associated transcripts correlates with tumor progression 
RCC patients who develop metastasis, have a poor prognosis with a 5-year survival rate of less 
than 15% (23). We observed a correlation of short survival with the incidence of metastasis (Fig. 
3A). Also high levels of transcripts for FoxP3 or CD68 correlated with the incidence of 
metastasis, whereas CD45 and CD3 expression did not (Fig. 3B). A correlation between 
macrophages and metastasis has been suggested for other cancer types (24). In this context, a 
role for the paracrine and autocrine axis of the colony-stimulating factor-1 (CSF-1) and the 
epidermal growth factor (EGF) (25) as well as for the actin-binding protein mammalian enabled 
(Mena) (26). However, in the cohort of primary ccRCC patients we analysed, we did not find a 
significant correlation between CSF-1, EGF, their receptors and Mena with survival 
(Supplementary Figure S1C). 
We found a significant correlation between low iNOS transcripts and increased tumor stage (pT) 
and a similar trend for high CD163 transcripts (Fig. 3C). These data suggest a progressive 
accumulation of or conversion to CD163high M2 macrophages at the expense of iNOShigh M1 
macrophages in ccRCC, which correlates with reduced survival of patients with ccRCC. 
 
ccRCC tumor cells contribute to M1  M2 conversion of myeloid cells 
To investigate whether freshly isolated ccRCC tumor cells can induce tumor-promoting changes 
in myeloid cells, we sorted P1 cells from blood and CD45
- cells from simultaneously processed 
tumor tissue samples and co-incubated P1 cells with autologous CD45
- cells for 48 h at a 1:3 ratio 
followed by analysis of P1 cells. Coculture induced an upregulation of CD163 and MR in blood-
derived myeloid cells on the protein level (Supplementary Fig. S6A). On the mRNA level a slight 
increase in the M2-related genes CD163, c-MYC and IL-10 was observed and a strong rise in 
FN-1 (Supplementary Fig. S6B). Furthermore, the M1-associated gene iNOS was induced in 
two samples while IL-12 was not expressed in two samples and lost in one sample upon 
coculture with tumor cells. Because we only had sufficient material from a limited number of 
patients, we could not investigate this phenomenon in more patients. 
In summary, the CD45+CD3-CD19-CD68+CD11b+CD163high T2 population, which is found in 
ccRCC tumors but not in paired blood samples, shows features of tumor-promoting TAMs with an 
M2-like signature. Our observation that the level of CD163 transcripts in the tumor correlates with 
reduced survival and increased pT supports this. Furthermore, we showed that tumor cells 
contribute to M1  M2 skewing, which is in line with the progressive accumulation of T2 TAMs in 
ccRCC.  
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The ccRCC microenvironment impacts on the phenotype and function of T cells 
We noticed a correlation of high transcript levels of FoxP3 and IL-10 with increased tumor stage 
(Supplementary Fig. S7), suggesting a progressive accumulation of Tregs and IL-10 in the 
tumor. To investigate the impact of the immunoregulatory tumor microenvironment on the 
phenotype and function of T cells we sorted CD45RA-CD4+ and CD45RA-CD8+ T cells from fresh 
ccRCC (Supplementary Table S4) and from paired blood samples. We sorted CD45RA- 
(antigen-experienced) T cells because the proportion of antigen-experienced T cells in tumors 
was much higher than in paired blood samples (Fig. 4A) and these T cells have a lower 
threshold for in vitro cytokine production upon stimulation than naïve T cells (27). Levels of 
transcripts for effector cytokines including TNF-, IFN-, IL-2 and for the cytotoxic effector 
molecule Granzyme B were higher in tumor-derived CD4+ and CD8+ T cells than in blood-derived 
CD4+ and CD8+ T cells (Fig. 4B, C). At the same time, however, tumor-derived T cells displayed 
high mRNA levels of immunoregulatory molecules including PD-1, Tim-3 and CTLA-4 and also of 
the immunosuppressive cytokine IL-10. Furthermore, tumor-derived CD4+ T cells expressed 
higher levels of the transcription factor FoxP3, IL-17 and the Th2 cytokines IL-4 and IL-13. Only a 
slight increase in TGF- was observed in TILs, which may be explained by the fact that TGF- is 
mainly regulated post translationally (Fig. 4B, C). By flowcytometry we confirmed the activated 
stage of TIL-derived T cells by the strong expression of the activation marker CD69 and also 
confirmed the increased expression of PD-1, Tim-3, CTLA-4 and FoxP3 on the protein level 
(Fig.5 A and B, Supplementary Fig. S8). Together these data suggest that ccRCCs are sites 
with an active immune response, which has features reminiscent of immune regulation or chronic 
inflammation (28, 29). 
To confirm the changed cytokine profile in tumor-derived T cells on the protein level and to 
investigate the role of the tumor microenvironment on these functional deviations towards a more 
regulated phenotype, we polyclonally stimulated CD45RA- antigen-experienced T cells in the 
presence of the entire tumor digest and compared their cytokine production with that of CD45RA- 
T cells from the same source but that were previously sorted. The production of the effector 
cytokines IFN- and IL-2 by sorted CD4+ T cells was higher, whereas the production of the 
immunoregulatory cytokine IL-10 was lower compared to the same T cells in the presence of 
their natural tumor environment (Fig. 6A). The difference in effector cytokine production between 
sorted and non-sorted cells was less pronounced for CD8+ T cells, whereas the production of IL-
10 was supported by the presence of the tumor (Fig. 6B). We detected a very low percentage of 
IL-17-producing cells that was comparable in sorted and non-sorted cells (Supplementary Fig. 
S9). We conclude that the tumor microenvironment induced skewing towards a more regulated 
phenotype upon T cell receptor (TCR)-dependent (anti-CD3/CD28-coated beads) as well as–
independent (PMA plus ionomycin) stimulation. 
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M2 TAMs impact on the cytokine profile of CD4+ T cells 
TAMs have been described to suppress tumor-specific immunity (30, 31). To investigate whether 
the T2 population in the tumor contributes to the immune subversion of tumor-infiltrating antigen-
experienced T cells, we stimulated sorted, blood-derived CD45RA-CD4+ cells with anti-
CD3/CD28-coated beads in the presence or absence of autologous, sorted, tumor-derived T2 
cells (CD45+CD2-CD19-CD11b+CD163high) (Supplementary Fig. S10). Because of limited 
availability of material, we could only perform TCR-dependent stimulation of CD4+ T cells. Blood-
derived CD4+ T cells produced significantly less IL-2 and significantly more TGF-, IL-10 and IL-4 
upon addition of autologous T2 TAMs (Fig. 7A). The production of the effector cytokines IFN- 
und TNF- followed the same trend as IL-2, although the effect was not statistically significant. 
Furthermore, the co-incubation with T2 TAMs resulted in an upregulation of transcripts for PD-1 
and Tim-3 (Fig. 7B). No changes in T cell function were observed when T cells were cocultured 
with the sorted T1 fraction (CD45
+CD2-CD19-CD11b+CD163low) (data not shown). There was a 
trend towards reduced proliferation of T cells in the presence of the T2 fraction, however data 
were not consistent (data not shown). These results indicate that CD45+CD2-CD19-
CD11b+CD163high cells contribute to functional and phenotypic immune subversion of tumor-
infiltrating T cells in ccRCC patients. 
 
 
DISCUSSION 
 
There is growing evidence that the immunoregulatory milieu, which is associated with most 
tumors, precludes protective anti-tumor immunity and presumably diminishes the efficacy of 
immunotherapy (32). To better understand local immunoregulatory processes that impact on 
disease progression, we correlated intratumoral immunological profiles with survival in patients 
with primary ccRCC. In addition, we performed functional experiments to dissect the mutual 
influences of tumor cells, TAMs and T cells.  
We retrospectively analyzed the transcripts for 31 immune response-related genes in a cohort of 
54 primary ccRCC FFPE tumor samples and correlated the expression of each of these genes 
with survival. In line with the finding that not the degree of leukocyte infiltration but rather 
leukocyte subtypes, their function and location are relevant to disease outcome (1) we did not 
observe a correlation of the degree of leukocyte infiltration (CD45) and survival. Data on the 
impact of tumor infiltrating leukocytes (TILs) on disease outcome in ccRCC are conflicting. 
Whereas one study showed that an increased frequency of CD8+ T cells correlates with poor 
prognosis, except when these T cells are proliferating (33), another study shows a correlation of 
increased Th1 type responses with good prognosis (34). Furthermore, a recent publication 
showed that increased presence of lymphocytes negatively impacts on overall survival (21). Of 
all lymphocyte-associated transcripts, only FoxP3, a transcription factor specific for regulatory T 
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cells (35) correlated with decreased survival, which confirms previously published findings (36, 
37). Tregs are a subpopulation of T cells that play an important physiological role in suppressing 
effector T cell responses to self-antigens thereby preventing autoimmunity (38).  Furthermore, 
Tregs suppress anti-tumor immunity (7, 39). A correlation between high numbers of Treg or a low 
Teffector/Treg ratio and reduced survival has been shown in several other cancer types including 
ccRCC (39, 40). 
We discovered that increased transcripts for the macrophage marker CD68 correlated 
significantly with reduced survival in primary ccRCC. Although most studies correlate an 
increased frequency of TAMs with unfavorable prognosis of patients with breast, prostate, 
bladder or kidney cancer, some studies with patients suffering from melanoma, stomach and 
colocrectal cancer find the opposite (summarized in(8)). A possible explanation for these 
conflicting observations may be the use of the pan-macrophage marker CD68, which recognizes 
all subsets of this heterogeneous and plastic population (41) and does not differentiate between 
functionally different M1 and M2 macrophages (42, 43). Pro-inflammatory M1 macrophages are 
induced by IFN- and LPS, whereas alternatively activated, anti-inflammatory M2 macrophages 
differentiate in the context of IL-4, IL-13 and IL-10 (5). M2 macrophages dampen immune and 
inflammatory responses to prevent tissue damage in the case of chronic inflammation (44). In the 
context of tumors, M2 macrophages promote tumor progression, metastasis and 
immunosuppression (43). For this reason we expanded our retrospective analysis with 12 TAM-
associated genes and found a correlation between M1-associated transcripts (iNOS) and 
prolonged survival as well as an association between M2-associated genes (CD163, FN-1 and 
IRF-4) and reduced survival. iNOS was correlated before with increased survival of patients with 
colorectal cancer (45). Furthermore, a correlation between CD163 and reduced survival has 
been recently observed in different cancers including ccRCC (46, 47). Subsequent analysis of 
prospectively collected fresh tumor samples showed the presence of two different myeloid 
fractions in primary ccRCC (CD11b+CD68+CD163high cells (T2 fraction) and 
CD11b+CD68+CD163low cells (T1 fraction), whereas we only found the 
CD11b+CD68+CD163lowcells (P1 fraction) in paired blood samples. The T2 population expressed 
high levels of MR, FN-1 and IL-10 and low levels of iNOS, thus uncovering CD163 as a marker 
for TAMs with an M2-like signature in ccRCC (5, 44). T2 cells – but not T1 or P1 cells – showed 
increased expression of molecules that are involved in negative immune regulation including PD-
L1 and IL-10. We noticed that differences in the CD163 signal between the different fractions 
were not as pronounced on the mRNA level as seen on the protein level. One explanation for this 
could be that transcripts of CD163 are less stable than the protein. The high level of MHC class II 
on the T2 fraction clearly discriminates them from CD11b
+ MHC-II-/low myeloid derived suppressor 
cells (MDSC) (6, 48). 
TAMs can support tumor progression in many ways including the promotion of tumor survival, 
invasion, metastasis and angiogenesis (8). Our analyses showed a correlation between CD68 
transcripts and an increased incidence of metastases. We observed a correlation between high 
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CD163 levels and high tumor staging (pT) and the opposite for iNOS. This suggests a 
progressive accumulation of M2 TAMs in ccRCC, which may be due to an increased influx of M2 
TAMs (10) or to in situ conversion of M1 to M2 macrophages (9, 48, 49). Our data supports the 
second scenario, since we observed the induction of M2-associated markers on blood-derived 
myeloid cells after coculture with autologous tumor cells. These findings are in line with another 
study showing that supernatants of ccRCC tumor cell lines induced the expression of M2 
markers in human macrophages (49). 
Our observation that transcript levels for CD163 but also for FoxP3 and IL-10 positively correlate 
with pT, suggests increasing immune regulation during tumor progression (7, 50, 51). Along this 
line, transcripts for the effector molecules TNF- and perforin positively correlated with survival 
whereas the opposite was true for CTLA-4 and IL-10. Functional analysis of TILs confirmed this: 
although TILs showed an antigen-experienced (CD45RO+) and activated (CD69+, IFN-+, TNF-
+) phenotype, they expressed higher levels of PD-1, Tim-3, CTLA-4 and IL-10 at the same time, 
all of which are indicative for immune regulation. The increased expression of PD-1 and Tim-3 
was more pronounced in tumor-derived CD8+ T cells, whereas CTLA-4 and FoxP3 expression 
was more prominent in tumor-derived CD4+ T cells. This suggests that CD4+ and CD8+ T cells 
may be subject to different mechanisms of immune regulation in the tumor. Especially, the 
significant increase of the PD-1+/Tim-3+ population is indicative for an exhausted T cell 
phenotype (52) and implies reduced effector function of CD8+ T cells within ccRCCs. The tumor 
environment itself, or more specifically, TAMs, contribute to the regulated phenotype of T cells 
because their effector function was partially rescued by sorting CD4+ and CD8+ T cells out of the 
tumor. The reversed experiment – addition of sorted CD11b+CD163high cells (T2 fraction) from 
primary ccRCC tumor samples to autologous blood-derived CD4+ T cells– confirmed the negative 
impact of TAMs on T cell effector function. 
In conclusion, we found that high infiltration of primary ccRCC by Tregs and M2 TAMs correlates 
with reduced survival. Furthermore, we showed a progressive accumulation of and/or conversion 
to M2 macrophages that is supported by tumor cells. M2 TAMs in turn induce skewing of tumor-
infiltrating T cells towards a more regulated phenotype at the expense of protective effector 
function.  
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FIGURES 
 
 
 
Figure 1: Transcripts of FoxP3, CD68, and genes associated to M2 TAMs inversely correlate with 
survival in patients with ccRCC 
 
54 ccRCC FFPE tumor samples were subjected to a retrospective qRT-PCR analysis for different 
immune response-related genes. ∆Ct levels of CD45 were calculated by normalization to the 
endogenous control (18SrRNA), ∆Ct levels of all other genes were calculated by normalization to 
CD45. Survival analysis was performed using the Cox proportional hazard model and, after 
dichotomizing the data based on the mean-expression level, also with the log-rank test of the 
Kaplan-Meier estimator. The results of both statistical tests are displayed for selected genes. 
Patients that were still alive at time of analysis are marked with a tick. Kaplan-Meier survival 
curves show the relation of gene expression with survival for (A) CD45, CD3, FoxP3 and CD68 
and (B) iNOS, CD163, FN-1 and IRF-4. Multivariate Cox regression analysis revealed that the 
correlation of target gene expression and survival is independent of pT for CD68: p=0.02, 
HR=0.704, 95% CI 0.520-0.954; iNOS:  p=0.011, HR=1.261, 95% CI 1.055-1.506 and CD163 
p=0.015, HR=0.645, 95% CI 0.453-0.919, as well as independent of patients’ age for CD68: 
p=0.04, HR=0.720, 95% CI 0.524-0.989; iNOS: p=0.012, HR=1.299, 95% CI 1.060-1.592 and 
CD163: p=0.013, HR=0.636, 95% CI 0.445-0.909. (C) ∆Ct levels of CD163 plotted against ∆Ct 
values of IL10, MR, FN-1 and iNOS. Results of Spearman Rho correlation analysis are depicted 
in the plots. Each dot represents an individual patient. 
RESULTS 
 
53 
 
 
Figure 2: Characterization of tumor-associated myeloid cells in ccRCC 
 
Fresh primary cRCCs and paired blood samples were collected and processed as described 
under Materials and Methods. (A) Dot plots display staining of PBMC (left histogram) and 
processed tumor (right histogram) for CD11b and CD163 after gating on CD45+ CD3- CD19- 
cells. P1, T1 and T2 designate individual myeloid populations. The plots show a representative 
example of one patient. (B) Expression of different macrophage-associated molecules after 
gating on the populations P1, T1 and T2, displayed as the geometric mean of fluorescence 
intensity. Each symbol represents an individual patient; means of each group and significant 
differences (* p<0.05) are displayed. (C) qRT-PCR analysis of FACS-sorted P1 and T2 fractions. 
Genes displayed on the left side of the vertical line are related to M2 TAMs, on the right side to 
M1 TAMs. CT levels were calculated by normalization to the endogenous control PPIA. Results 
are presented as fold change in expression level of T2 relative to P1; the geometric mean of each 
group is depicted. Fold differences in expression within the shaded area are considered as not 
significant. Symbols at the 0.0001 line on the y-axis represent samples of which the fold change 
could not be calculated, since expression was only detected in one of the fractions. Each symbol 
represents an individual patient in B and C. 
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Figure 3: Positive correlation of FoxP3 and CD68 gene expression with the incidence of 
metastasis and of M2 TAM-associated genes with tumor stage 
 
(A) Survival in months after diagnosis, (B)  ∆Ct levels of CD45, CD3,  FoxP3 and CD68 
correlated with the incidence of metastasis (0= patient did not develop metastasis, 1= patient 
developed metastasis). (C) CT levels of CD163 and iNOS correlated with tumor stage (pT). 
Each dot represents an individual patient. ∆Ct levels of target genes were calculated as 
described for Fig. 1. Only when correlations are significant, the results of the Spearman Rho 
correlation test are displayed within the plot. Tumor stage was defined as: 1= pT1, 1.25= pT1a, 
1.5=pT1b, 2=pT2, 3=pT3, 3.25=pT3a, 3.5=pT3b, 3.75=pT3c and 4=pT4. 
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Figure 4: Tumor-derived T cells show an antigen-experienced and regulated phenotype  
 
(A) The percentage of CD45RA- (antigen-experienced) T cells in blood and tumors of ccRCC 
patients was determined by flowcytometry; the means of each group and significant differences  
(* p<0.05) are displayed. (B, C) Gene expression analysis was performed by qRT-PCR on 
FACS-sorted CD45RA- CD8+ (B) and CD45RA- CD4+ (C) from blood and tumors of ccRCC 
patients. Ct values were normalized to the endogenous control PPIA. Results are presented as 
fold change in expression level of tumor-derived relative to blood-derived T cells; the geometric 
mean of each group is depicted; fold differences in expression within the shaded area are 
considered as not significant. Each symbol represents an individual patient. 
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Figure 5: Tumor-derived T cells express higher levels of regulatory molecules than T cells 
derived from paired blood samples 
 
FACS analysis on tumor- and blood-derived cells after gating on CD8+CD45RA- T cells (A) or 
CD4+CD45RA- T cells (B). The graphs display the percentage of cells positive for a particular 
marker. A representative staining is shown in Supplementary Fig. S4. Each symbol represents an 
individual patient. The mean of each group and significant differences (* p<0.05; ** p<0.005;     
*** p<0.0005) are depicted.  
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Figure 6: The tumor microenvironment impacts on the cytokine profile of T cells 
 
Intracellular staining for cytokines after 6h ex vivo stimulation with anti-CD3/CD28 beads or with 
PMA + ionomycin in the presence of brefeldin A and monensin.  Cells were stimulated within the 
tumor digest or after sorting of CD45+ CD4+ T cells (A) or CD45+ CD8+ T cells (B) and analyzed 
after gating on live CD45+ CD4+ T cells (A) or live CD45+ CD8+ T cells (B). Each symbol 
represents an individual patient. Results of unsorted and sorted T cells from the same patient are 
connected by a thin line. The mean of each group and significant differences (* p<0.05;               
** p<0.005) are depicted.  
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Figure 7: ccRCC-derived M2 TAMs skew T cells towards a more regulated phenotype 
 
Sorted blood-derived CD4+ T cells were cultured for 48 h with or without sorted autologous        
T2 cells (CD45
+CD2-CD19-CD11b+CD163high) in a ratio of 1:1. (A) Production of cytokines was 
assessed via ICS after 6h ex vivo stimulation with anti-CD3/CD28 beads in the presence of 
brefeldin A and monensin after gating on live CD45+ CD11b- CD4+ cells. Results of the same 
patient are connected by a thin line. The mean of each group and significant differences             
(* p<0.05; ** p<0.005) are depicted. (B) The expression of regulatory molecules was assessed by 
qRT-PCR. ∆Ct levels were calculated by normalizing the Ct values of the target genes to the Ct 
values of CD4. Results are presented as fold change in expression level of CD4+ T cells 
cocultured with autologous T2 cells (CD45
+CD2-CD19-CD11b+CD163high) relative to CD4+ T cells 
cultured without. Fold differences in expression within the shaded area are considered as not 
significant. The symbol at the 10’000 line on the y-axis represents a sample of which fold change 
could not be calculated, since expression was only detected after coculture. Each symbol 
represents an individual patient. 
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SUPPLEMENTARY FIGURES AND TABLES 
 
Supplementary Table S1: Summary of Taq Man Assays used for retrospective screen 
  Target  Gene Symbol  Taq Man Assay ID    Target  Gene Symbol  Taq Man Assay ID  
A  CD45  PTPRC  Hs00236304_m1  B  iNOS  NOS2  Hs01075529_m1  
  CD3  CD3G  Hs00962186_m1    CD163  CD163  Hs00174705_m1  
  CD4  CD4  Hs00181217_m1    MR (CD206)  MRC1;MRC1L1  Hs00267207_m1  
  CD8  CD8A  Hs00233520_m1    FN-1  FN1  Hs01549976_m1  
  CD68  CD68  Hs00154355_m1    IRF-4  IRF4  Hs01056533_m1  
  MHC class-I  HLA-C  Hs03044135_m1    IRF-5  IRF5  Hs00158114_m1  
  MHC class-II  HLA-DRA  Hs00219575_m1    IL-12  IL12B  Hs01011518_m1  
  CTLA-4  CTLA4  Hs00175480_m1    EGF  EGF  Hs01099999_m1  
  FoxP3  FOXP3  Hs01085834_m1    EGFR  EGFR  Hs01076078_m1  
  Tim-3  HAVCR2  Hs00262170_m1    CSF-1  CSF1  Hs00174164_m1  
  PD-1  PDCD1  Hs00169472_m1    CSF-1R  CSF1R  Hs00911250_m1  
  PD-L1  CD274  Hs00204257_m1    Mena  ENAH  Hs00403109_m1  
  BTLA  BTLA  Hs00699198_m1  C  IL-4  IL4  Hs00174122_m1  
  HVEM  TNFRSF14  Hs00187058_m1    IL-13  IL13  Hs00174379_m1  
  CD200  CD200  Hs01033303_m1  D  c-MYC  MYC  Hs00905030_m1  
  IDO  IDO1  Hs00984148_m1  
      Arginase 1  ARG1  Hs00968979_m1  
      NKG2D  KLRK1  Hs00183683_m1  
      MICA  MICA  Hs00741286_m1  
      MICB  MICB  Hs00792952_m1  
      IL-10  IL10  Hs00961622_m1  
      TGF-b  TGFB1  Hs00998133_m1  
      IL-17a  IL17A  Hs00174383_m1  
      TNF-a  TNF  Hs00174128_m1  
      IFN-g  IFNG  Hs00174143_m1  
      IL-2  IL2  Hs00174114_m1  
      Perforin  PRF1  Hs00169473_m1  
      Granzyme B  GZMB  Hs00188051_m1  
      LT-a  LTA  Hs00236874_m1  
      LT-b  LTB  Hs00242739_m1  
      LT-bR  LTBR  Hs00158922_m1  
     
Taq Man Assays used for initial screen (A), for TAM-related screen (C), and to further 
characterize sorted CD4+ T cells (C) and myeloid fractions (D). 
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Supplementary Table S2: Patients’ characteristics of received FFPE material 
          
Histology 
 
clear cell renal cell carcinoma 
  
   
  
Patient number 
 
n=54 
 
  
  
   
  
Age (years) 
 
40-86 (66.3 ± 7.2)   
  
   
  
Survival time (months) 0-213 (80.9 ± 64.2)   
  
   
  
Pathological Stage 
 
pT1 2   
  
 
pT1a 3   
  
 
pT1b 16   
  
 
pT2 4   
  
 
pT3 8   
  
 
pT3a 6   
  
 
pT3b 13   
  
 
pT3c 1   
  
 
pT4 1   
          
 
Information is only displayed for those patients who died of tumor-related causes. 
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Supplementary Figure S1: Immune profile of ccRCC correlates with survival 
 
54 ccRCC paraffin-embedded tumor samples were subjected to a retrospective qRT-PCR 
analysis for 43 different immune response-related genes. ∆Ct levels of CD45 (A) were calculated 
by normalization to the endogenous control (18s rRNA), ∆Ct levels of all other genes were 
calculated by normalization to CD45. Transcripts were quantified using original cDNA (A, B) or 
preamplified cDNA (C). Survival analysis was performed using the Cox proportional hazard 
model and, after dichotomizing the data based on the mean-expression level, also with the log-
rank test of the Kaplan-Meier estimator. Kaplan-Meier curves are shown to represent the relation 
of the expression of the different target genes with survival and the results of both statistical tests 
are displayed underneath the plot. Patients that were still alive at time of analysis are marked 
with a tick. Some genes (marked with an asterisk) were only detected in very low amounts, and 
in some samples no signal was observed for those genes. Survival analysis was therefore 
performed once including the no-signal samples by giving an estimated value (Ct=40), and once 
after excluding the no signal samples from the analysis. The results with or without the no-signal 
samples were similar for all genes except for IL-10 and CTLA-4. Plots calculated after inclusion 
of all samples are displayed (A, C), and for CTLA-4 and IL-10 also after exclusion of the no-
signal samples (B). Expression of Arginase-1, IL-2, LT-a, BTLA and IL-17 was not detected in the 
majority of samples and therefore not considered for survival analysis. 
 
 
 
 
 
 
 
 
 
Supplementary Figure S2: Correlation between CD68 expression measured by qRT-PCR and by 
immunohistochemistry 
 
Tumor sections of selected patients were stained for CD68 by immunohistochemistry (brown 
staining). Scans of microscopy slides at a magnification of 20x are shown. qRT-PCR analysis of 
the corresponding paraffin punches normalized to the endogenous control 18SrRNA revealed 
following ∆Ct values (A): 14.07, (B): 14.19, (C): 15.63, (D): 18.47.  
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Supplementary Figure S3: ∆CT levels of original cDNA correlate with ∆CT levels of 
preamplifiedcDNA 
 
cDNA of paraffin-embedded tumor material was preamplified to enable the evaluation of 
additional genes. The ∆Ct levels of the original cDNA were plotted against the ∆CT levels of the 
preamplified cDNA for CD68 and CD163. ∆Ct was calculated by normalizing Ct values to the Ct 
values of CD45. Each symbol represents an individual sample. Result of Spearman Rho 
correlation test is displayed in the graph.  
 
 
 
 
RESULTS 
66 
 
 
 
Supplementary Figure S4: Representative staining for regulatory molecules on T1, T2 and P1 
myeloid populations 
 
PBMCs and paired TILs were stained and T1, T2 and P1 subpopulations were determined after 
gating on live CD45+CD3-CD19- cells. Representative dot plots of PBMCs (left) and TILs (right) 
are shown and histograms of the expression of CD68 (intra-cellular), CD163, PD-L1, MR and 
MHC class-II after gating on T1, T2 and P1.  
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Supplementary Figure S5:  Comparison of T2 and T1 fraction via qRT-PCR analysis 
 
qRT-PCR analysis of FACS-sorted  T2 and T1 fractions. Genes displayed on the left side of the 
vertical line are related to M2 TAMs, on the right side to M1 TAMs. ∆Ct levels were calculated by 
normalizing the Ct values of the target genes to the Ct values of PPIA. Results are presented as 
fold change in expression level of T2 relative to T1. Fold differences in expression within the 
shaded area are considered as not significant. Symbols at the 10000 or 0.0001 line on the y-axis 
represent samples of which the fold change could not be calculated, since expression was only 
detected in one of the fractions. Each symbol represents an individual patient. 
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Supplementary Figure S6: Tumor cells promote transition of an M1 to an M2 phenotype 
 
FACS-sorted blood-derived CD11b+ cells were cultured with and without sorted autologous 
CD45- tumor cells for 48 h at a 1:3 ratio. (A) Results of FACS staining for different macrophage-
associated markers after gating on CD45+CD11b+ cells. (B) qRT-PCR for different M1- and M2-
associated genes after preamplification of the cDNA. Genes displayed on the left side of the 
vertical line are related to M2 TAMs, on the right side to M1 TAMs. ∆Ct levels were calculated by 
normalizing the Ct values of the target genes to the Ct values of CD45. Results are presented as 
fold change in expression level of CD11b+ cells cocultured with CD45-tumor cells (P1+tumor) 
relative to CD11b+ cells cultured without (P1 alone). Fold differences in expression within the 
shaded area are considered as not significant. Symbols at the 10000 or 0.0001 line on the y-axis 
represent samples of which the fold change could not be calculated, since expression was only 
detected in one of the fractions. Each symbol represents an individual patient. Geometric means 
of each group are depicted. 
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Supplementary Figure S7: Positive correlation of FoxP3 and IL-10 with tumor progression 
 
qRT-PCR was performed on cDNA of FFPE material from ccRCC tumors and gene expression 
was correlated with tumor stage (pT). Results of Spearman Rho correlation analysis are shown 
for FoxP3 and IL-10. Each symbol represents an individual patient. ∆Ct levels were calculated by 
normalizing the Ct values of the target genes to the Ct values of CD45. pT was defined as        
1= pT1, 1.25= pT1a, 1.5=pT1b, 2=pT2, 3=pT3, 3.25=pT3a, 3.5=pT3b, 3.75=pT3c and 4=pT4. 
 
 
 
 
Supplementary Table S3: Patients’ characteristics of fresh tumor material 
 
        
Histology clear cell renal cell carcinoma 
  
  
  
Patient number n=20 
 
  
  
  
  
Age (years) 37-84 (60.5 ± 11)   
  
  
  
Pathological Stage pT1 0   
  pT1a 9   
  pT1b 3   
  pT2 3   
  pT3 0   
  pT3a 3   
  pT3b 2   
  pT3c 0   
  pT4 0   
        
 
 
 
 
RESULTS 
70 
 
 
 
 
Supplementary Figure S8: 
Representative staining of co-inhibitory 
molecules on blood- and tumor-derived 
T cells 
 
PBMCs and autologous TILs were 
stained with fluorochrome-labeled 
antibodies for specific surface markers 
and their expression is depicted after 
gating on (A) live CD45+CD3+ cells, on 
(B) live CD45+CD4+ cells or on            
(C) live CD45+CD8+ cells.  
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Supplementary Figure S9: The tumor microenvironment does not impact on the capacity of CD4+ 
T cells to produce IL-17 
 
Intracellular staining for IL-17 after 6h ex vivo stimulation with anti-CD3/CD28 beads or with PMA 
+ ionomycin in the presence of brefeldin A and monensin. Cells were stimulated within the tumor 
digest or after sorting of CD45+CD4+ T cells and were analysed after gating on live CD45+CD4+  
T cells. Each symbol represents an individual patient and the mean of each group is depicted. 
Results of unsorted and sorted T cells from the same patient are connected by a thin line. 
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Supplementary Figure S10: Sorting strategy for myeloid cells and T cells from ccRCCs and blood 
 
Sorting strategy for the simultaneous isolation of myeloid cells and T cells from (A) digested 
ccRCC tumors and (B) autologous PBMCs. After exclusion of cell debris, gates were set on 
CD45+ cells. For the sorting of T cells gates were set on CD2+ cells, CD16- CD19- and CD56- 
cells, followed by gating on CD45RA- cells and finally on either the CD4+ or CD8+ population. For 
the isolation of myeloid cells gates were set on CD2- cells, then on CD16- CD19- and CD56- cells, 
and finally on the CD11b+ CD163low population (P1 and T1 fraction) or on the CD11b+CD163
high 
population (T2 fraction). 
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MATERIALS AND METHODS 
 
Patient material 
(i) Paraffin embedded material: Formalin-fixed, paraffin-embedded material from 60 patients 
with ccRCC, collected within the years 1993 to 2003 were identified in the archives of the 
Department of Pathology, University Hospital Zurich. Patients met the same criteria as described 
above for fresh patient material. The local ethical committee approved this study (KEK ZH Ref. 
nr, STV38-2005). Six patients died of causes not related to cancer and were excluded from the 
analysis. A summary of the patients’ characteristics can be found in Supplementary Table S2.  
(ii) Fresh ccRCC tumor samples and blood: 20 renal cancer patients were enrolled in the 
study. The patients underwent full or partial nephrectomy as part of their standard treatment at 
the Department of Urology, University Hospital Zurich. Tumor samples and peripheral blood were 
prospectively collected following informed consent in accordance with the Declaration of Helsinki. 
The local ethics committee and Swissmedic approved the study (EK-1017). All patients met the 
following criteria: a) a new renal tumor diagnosis with histological confirmation of a clear cell 
renal tumor subtype according to the 2004 WHO classification of renal tumors; b) no prior 
treatment for kidney cancer. A summary of the patients’ characteristics can be found in 
Supplementary Table S3. PBMCs were isolated from peripheral whole blood by Ficoll (Ficoll-
PaqueTM PLUS; GE Healthcare) density centrifugation. The tumor material was cut into multiple 
pieces of 2-4 mm3 and further dissociated with DNase I Type IV (6 U/mL, Sigma) and 
Collagenase IV (1 mg/mL, Sigma) in DMEM (Gibco) plus Penicillin and Streptomycin (50 U/mL, 
Gibco) for 1-2 hours at 37 °C. The digested material was afterwards filtered and the obtained 
single cell suspension and the PBMCs were cryopreserved at -80°C until further analysis. 
 
Flow Cytometry for phenotypical analysis 
Surface staining with fluorochrome-conjugated antibodies was performed in PBS (NaCl (136mM, 
Fluka), Na2HPO4 (8mM, Roth), KH2PO4 (1.5mM, Roth), pH7) together with live/dead staining 
(LIVE/DEAD® Fixable Violet Dead Cell Stain Kit, Invitrogen) for 20 min at room temperature. 
Intracellular staining for CD68 and FoxP3 was performed according to manufacturer’s 
instructions (eBioscience). Staining was measured with a flow cytometer (CyAn ADP 9, Beckman 
Coulter) and data were analyzed with FlowJo software (TreeStar). All antibodies used in 
this study are listed in the supplementary materials and methods section and were 
purchased from BioLegend, BD Biosciences, Beckman Coulter or eBioscience. 
 
FACS sorting of T cells and TAMs from TILs and PBMCs 
TILs and PBMCs were stained in sorting buffer (SB: PBS containing 2 % pooled human serum 
(PAA Laboratories) and 6 U/mL DNase I TypeIV (Sigma)) and stained with a mixture of 
fluorochrome-conjugated antibodies plus live-dead staining (LIVE/DEAD® Fixable Violet Dead 
Cell Stain Kit, Invitrogen). After staining for 20 min at 4 °C cells were washed and resuspended in 
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SB. Cells were either gated on CD45+CD8+ T cells and on CD45+CD4+ T cells, or in the case of 
simultaneous sorting of T cells and myeloid cells as shown in the gating strategy 
(Supplementary Fig. S10), and the different populations were sorted using a FACSAria III cell 
sorter (BD Biosciences).   
 
Polyclonal stimulation and intracellular cytokine staining (ICS)  
After sorting, cells were rested overnight in a 96-well round-bottom plate in TC-RPMI (RPMI 
(Gibco), supplemented with NaHCO3 (2 g/L, Sigma), L-glutamine  (2 mM, Sigma), Penicillin and 
Streptomycin (50 U/mL, Gibco), MEM nonessential amino acids (1X, Gibco), sodium pyruvate (1 
mM, Gibco), 10−4 M β-mercaptoethanol (Sigma) and 10% pooled human serum) plus DNase I (6 
U/mL, Sigma). T cells (at least 10’000 per well) were either cultured alone or with the tumor 
digest or with TAMs (ratio 1:1).  After overnight resting, T cells were stimulated in 96-well plates 
in the presence or absence of the tumor digest or TAMs with anti-CD3/CD28 Dynabeads (Ratio T 
cells: beads was 1:3; Invitrogen, Cat. No. 111.41D) or with PMA (50 ng/mL Sigma) plus 
ionomycin (500 ng/mL, Sigma). Stimulation was performed for 6 h at 37 °C in TC-RPMI 
supplemented with Brefeldin A (10 µg/mL, Sigma) and DNase I Type IV (6 U/mL, Sigma). Cells 
were surface stained with a fluorochrome-conjugated antibody cocktail including live-dead 
staining (LIVE/DEAD® Fixable Violet Dead Cell Stain Kit (ViViD), Invitrogen) in PBS for 20 min at 
room temperature in the dark. Subsequently, cells were fixed in 4% formalin (Kantonsapotheke 
Zürich) and permeabilized with permeabilization buffer (PB: PBS supplemented with 2% FCS, 20 
mM EDTA, 0.05% NaN3, and 0.1% Saponin). For intracellular staining, cells were incubated with 
a mix of fluorescent-conjugated antibodies in PB for 20 min at room temperature in the dark. 
Cells were washed once with PB and resuspended in PBS containing 1% formalin before 
analysis by flow cytometry as described before. Antibodies used are listed in the supplementary 
material and methods section. When stimulation of T cells was performed in presence or 
absence of the tumor microenvironment cytokine production was measured after gating on 
ViViD- CD45+ CD14- CD16- CD19- CD8+ or CD4+ T cells, and in presence or absence of TAMs 
after gating on ViViD- CD45+ CD11b- CD4+ T cells. 
 
RNA isolation 
After FACS sorting and after co-culture experiments a portion of the cells (at least 500 cells) was 
resuspended in TRI Reagent (Ambion) and frozen at -80 °C until RNA isolation. RNA was 
isolated using a MagMAXTM-96 for Microarrays Total RNA isolation kit (AM1839 Ambion) by the 
No-Spin Procedure according to the manufacturer’s instructions. RNA isolation from FFPE 
material was performed using Trizol as described in the supplementary material and methods 
section. 
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Real-time quantitative reverse transcription–polymerase chain reaction (qRT-PCR) 
The concentration and purity of RNA was evaluated using the NanoDrop ND-1000 
spectrophotometer (NanoDrop Technologies). 500 ng of RNA was reverse transcribed using the 
high-capacity cDNA Reverse Transcription Kit (Applied Biosystems). The obtained cDNAs were 
stored at -20 °C until qRT-PCR analysis. Because of limited material, cDNA of sorted cells and 
paraffin punches was preamplified. Preamplification was performed for 14 cycles according to 
manufacturer’s instructions (TaqMan® PreAmp Master Mix Kit, Applied Biosystems). We tested 
the correlation of expression analysed on original cDNA with that analysed on preamplified cDNA 
for selected highly expressed (CD45, CD68, CD163, TNF-, MHC-II) and lowly expressed genes 
(iNOS, FoxP3, IL-10, IDO) and found an excellent correlation for all, confirming uniform 
preamplification for all samples (CD68 and CD163 are shown in Supplementary Fig. S3). qRT-
PCR was done on a Rotor-Gene Q real-time PCR cycler (Qiagen) using commercially available 
predeveloped TaqMan reagents with optimized primer and probe concentrations (TaqMan® gene 
expression assays, Applied Biosystems) (Supplementary Table S1).  
After an initial hold for 2 min at 50 C and 10 min at 95 C the probes were cycled 45 times at 95 C 
for 15 sec and at 60 C for 60 sec. All PCR reactions were performed in triplicates. Threshold 
cycle (Ct) values were determined with the Rotor-Gene Q Series software 1.7. Ct values were 
calculated by normalizing the target mRNA levels to (i) the endogenous control 18S rRNA 
(Hs03928990_g1), (ii) the endogenous control PPIA (Hs99999904_m1), or (iii) to the levels of 
CD4 as stated in the figure legends. Immune response-related genes other than CD45 were 
normalized to CD45. Because there was no correlation between CD45 transcripts and survival 
(Fig. 1A), this normalization will not obscure potential correlations between the expression of 
other immune response-related genes and survival. In some cases Ct levels were expressed as 
relative to the appropriate control. Therefore Ct values were determined (Ct target gene-Ct 
control) and fold change calculated with the formula 2-Ct.Ct values >38 cycles were interpreted 
such that the gene is not expressed. Fold changes in the range of a fold increase of <2 and a fold 
decrease of <0.5 was considered as not significant. This range was illustrated as shaded area in 
the figures.  
 
Statistical analysis  
The relationship between the expression of the target genes and patient survival was analysed 
using a univariate Cox proportional hazard regression model with 95% confidence intervals. 
Prognostic effect of variables that showed a correlation with survival in univariate analysis was 
tested for dependence on age at operation and pT by multivariate Cox regression analysis. 
Furthermore, data was dichotomized based on mean gene expression value of all analysed 
samples, log-rank test performed and Kaplan-Meier curves generated in which probability of 
overall survival was plotted over time. Correlations between different parameters were assessed 
using the Spearman Rho correlation test (IBM SPSS statistics software). Wilcoxon matched-pairs 
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signed rank test was used to analyse statistical significance between groups (GraphPad Prism 
Software). The criterion for significance was set at p≤0.05. 
 
 
SUPPLEMENTARY MATERIALS AND METHODS 
 
Antibodies used in this study were purchased from BioLegend (BL), BD Biosciences (BD), 
Beckman Coulter (BC) and eBioscience (eB). 
 
Flow Cytometry for phenotypical analysis 
Cells were stained with combinations of following fluorochrome-conjugated antibodies CD4 FITC 
(BD), Tim-3 PE (BL), CTLA-4 PE (BL), CD8 ECD (BC), CD3 PerCP (BL), PD-1 PE-Cy7 (BL), 
CD69 PE-Cy7 (BL), CD45RA PacificBlue (eB), CD45 KromeOrange (BC), FoxP3 APC (eB), 
CD45RA APC (BL), CD25 APC-Cy7 (BD), CD68 FITC (eB), PD-L1 PE (BL), CD14 ECD (BC), 
MR PerCPCy5.5 (BL), CD11b PE-Cy7 (BL), CD3 PacificBlue (BL)e, CD19 PacificBlue (BL), 
CD45 KromeOrange (BC), CD163 APC (BL) or PD-L1 APC (BL), HLA-DR APC-Cy7 (BL).  
 
FACS sorting of T cells and TAMs from TILs and PBMCs 
(i) Sorting of T cells only: processed tumors or PBMC 
Surface staining mix: CD45 PerCP-Cy5.5 (BL), CD8 ECD (BC) and CD4 KromeOrange (BC). 
(ii) Sorting of T cells plus TAMs: processed tumors or PBMC  
Surface staining mix: CD45 KromeOrange (BC), CD19, CD16, CD56 PacificBlue (all BL), CD8 
ECD (BC), CD4 FITC (BD), CD11b PE-Cy7 (BL), CD163 APC (BL), CD2 PerCP-Cy5.5 (BL), and 
CD45RA PE or PacificBlue (both eB). 
 
Polyclonal stimulation and intracellular cytokine staining (ICS)  
(i) Stimulation of T cells in presence or absence of tumor microenvironment 
Surface staining mix: CD45 PerCP-Cy5.5 (BL), CD8 ECD (BC), CD4 KromeOrange (BC), CD14, 
CD16, CD19 PacificBlue (all BL); intracellular staining mix: IFN- FITC (BC), IL-17 PE (eB), IL-2 
PE-Cy7 (BL), IL10 APC (eB).  
(ii) Stimulation of T cells in presence or absence of TAMs 
Surface staining mix: CD45 KromeOrange (BC), CD4 FITC (BD), CD11b PacificBlue (BL) with 
(A) or without TGF-1 (LAP) PE (BL) (B); intracellular staining mix: (A) IL-4 PE-Cy7 (BL), IL-2 
PerCP-Cy5.5 (BL), IL-10 APC (eB), (B)  IL17 PE (eB), IFN- PE-Cy7 (BL), IL-13 APC (BL), TNF-
 PerCPCy5.5 (BL).  
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RNA isolation from paraffin material 
Deparaffinization of the paraffin punches was performed in 300 µL elution buffer (1 M Tris pH 8, 
0.5 M EDTA pH 8, 20% SDS (all Ambion), ultrapure water (Sigma)) for 10 min at 95°C while 
shaking. Samples were subsequently centrifuged (Eppendorf centrifuge 5417R, Omnilab) for 
10 min at 14’000 rpm and 4°C and digested with 3 μL of Proteinase K (18 +/- 4 mg/ml, Roche) for 
72 hours at 55°C. Thereafter samples were centrifuged for 2 min at 14’000 rpm and 4°C and 250 
µL of the obtained supernatants were transferred into new tubes. 750 µL TRIzol LS Reagent 
(Invitrogen) was added to each sample and tubes were mixed by vortexing. Samples were 
homogenized by centrifugation for 2 min at 14’000 rpm and 4°C using QIA-shredder columns. 
RNA purification was performed by phenol and chloroform extractions: 200 µL of chloroform was 
added to each flow-through, then samples were mixed by inverting the tubes, incubated at room 
temperature for 5 min until two phases were visible and centrifuged for 15 min at 14’000 rpm and 
4°C. The upper aqueous phase containing the RNA was transferred into a new tube, 20 µg 
glycogen (Invitrogen) was added and the RNA precipitated by adding 0.5 mL isopropanol (99.9% 
V/V, Kantonsapotheke Zürich). Samples were subsequently incubated for 15 min at room 
temperature and centrifuged for 20 min at 14’000rpm and 4°C. After removing the supernatant 
the pellet was washed with 1 mL 75% ethanol (absolute for analysis, Merck), air-dried, dissolved 
in RNase free water (Sigma) and digested with 80 U/ml DNAse I (New England Biolabs) for 15 
min at room temperature followed by an inactivation by 2 mM EDTA (Ambion) for 10 min at 65°C. 
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2.3 Supplemental results 
 
In addition to the results presented in part 2.1 and 2.2 I performed supplemental experiments and 
analysis that are not included in the manuscripts and are displayed and discussed in the 
appendix. 
 
 
2.4  Collaborative projects 
 
I contributed to collaborative projects with Dr. Rowayda Peters (University Hospital Zurich, 
Department of Oncology, Zurich, Switzerland) and Dr. Natko Nuber (University Hospital Zurich, 
Department of Oncology, Lab of Tumor immunology, Zurich, Switzerland). My contribution 
resulted in two co-authorships. The manuscripts are not further discussed in the scope of this 
thesis. For details please refer to the appendix. 
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3.  DISCUSSION 
 
After a debate on anti-tumor immunity for over more than 150 years it is by now well accepted 
that the immune system can recognize and destroy tumor cells. The fact that we observed T cell 
responses towards the TAA Cyclin D1 (CCND1) in the blood of ccRCC patients indicates that 
also in ccRCC immunosurveillance occurs.  
 
There is growing evidence that analysis of phenotype and functions of T cells in the peripheral 
blood often do not reflect the situation within tumors. It was for example shown that Melan-A 
specific T cells in the blood of melanoma patients were able to lyse melanoma cells, whereas 
Melan-A specific T cells isolated from TILs were functionally impaired (184). When we analyzed 
T cell responses towards CCND1 in TILs of those patients that showed a CCND1-response in 
PBMCs we could not detect CCND1-specific T cell responses in TILs of any of the patients 
tested. One explanation could be the reduced quality of TILs compared to PBMCs. However, it 
could also well be that T cells within TILs are not able to respond to antigenic stimulation due to 
the suppressive impact of the tumor microenvironment on T cell function as we observed in the 
case of polyclonal stimulation experiments. Since we could detect CCND1-specific T cells in TILs 
via tetramer staining, but not via intracellular cytokine staining, we hypothesize that CCND1-
specific cells were present within TILs, but the tumor microenvironment made them unable to 
respond to antigenic-stimulation. 
 
Hanahan and Weinberg added tumor promoting inflammation and the escape of the tumor from 
immune attack recently as emerging hallmarks of cancer (185). TAMs are part of the tumor 
microenvironment and they are known to be involved in many processes leading to tumor 
progression, such as angiogenesis, metastasis, but also the suppression of anti-tumor immunity 
(142). Macrophages isolated from lymph nodes of melanoma patients were for example shown to 
down-regulate the tumor-specific cytotoxicity of T cells and NK cells (186). TAMs have a poor 
antigen-presenting capacity and produce suppressive mediators like IL-10 and TGF- that leads 
to an inhibition of T cell activation and proliferation (143). We observed a significant increase in 
IL-10 production from T cells when incubated with TAMs, confirming the results of a recently 
published paper on the immunoregulatory effect of ccRCC-infiltrating TAMs (187). In addition to 
that, we showed that T cells produce less effector cytokines and increased amounts of Th2 
cytokines in the presence of TAMs. While in some studies an increase of FoxP3 and CTLA-4 was 
detected in T cells upon coculture with TAMs isolated from ccRCC (187), we observed an 
increase in the immunoregulatory molecules PD-1 and Tim-3. These results suggest that TAMs 
may use multiple mechanisms to skew T cells into a more regulated phenotype and functional 
state, favoring escape of ccRCC from the immune control.  
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It was shown that TAMs are unable to produce IL-12 and therefore induce Tregs instead of 
triggering a Th1 response (188). M2 macrophage polarization induces the production of a distinct 
panel of chemokines, such as CCL17, CCL22 and CCL24. The corresponding chemokine 
receptors CCR4 and CCR3 are expressed on Th2 cells and Tregs, which results in a recruitment 
of these cells and to an amplification of a Th2 polarized response (189). Furthermore, human 
monocytes were shown to differentiate into M2-like macrophages in the presence of 
CD4+CD25+FoxP3+ Tregs mediated by Treg-derived IL-10 (190). In accordance with this, we 
detected a significant correlation between CD68 and FoxP3 mRNA levels in our patient cohort of 
fresh tumor samples (Figure D-1), suggesting a simultaneous accumulation of Tregs and TAMs 
within ccRCC tumors. Both cell types were shown to negatively impact on patient prognosis in 
different cancer types (142, 191, 192), what we confirmed for ccRCC. Furthermore CD163 and 
the M2-like genes FN-1 and IRF-4 correlated with reduced survival in our patient cohort. CD163 
was associated before with TAMs bearing a M2-like phenotype and a correlation with reduced 
survival has been recently observed in different cancers including ccRCC (152, 193, 194).  
 
 
 
Figure D-1: Correlation of FoxP3 and CD68 mRNA levels in fresh ccRCC tumor samples 
qRT-PCR analysis was performed on cDNA of fresh RCCs. Spearman’s Rho correlation test 
revealed a significant correlation between FoxP3 and CD68 mRNA levels. 
 
We observed increased levels of the M1-marker iNOS in small tumors and high levels of the M2-
marker CD163 in large tumors. A transition of M1 polarization toward M2 polarization during 
tumor progression was already suggested by Mantovani and colleagues (112). The observed 
induction of M2-realted genes in CD11b+ cells when incubated with ccRCC tumor cells support 
the idea that ccRCC tumor cells directly impact on M1 to M2 polarization (152). It was proposed 
that the M1 to M2 transition goes in line with the establishment of an immunoregulatory milieu 
during the immunoediting process leading to tumor immune-escape (112). We detected a 
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positive correlation of high expression levels of FoxP3 and IL-10 with increased pT indicative for 
the development of an immunoreguatory milieu during tumor progression. The finding that larger 
tumors contain more IL-10 than small tumors supports data from a previous study on ccRCC 
(187).  
 
Based on the results of this thesis we hypothesize the following scenario of immunoregulation 
during ccRCC development (illustrated in Figure D-2): 
 
 
 
Figure D-2: Immunoregulation in ccRCC  
The establishment of an immunoregulatory milieu with increased levels of IL-10 and Tregs goes 
in line with a switch from M1 macrophages to M2-like macrophages promoting immune escape, 
tumor progression and metastasis (figure created by Maries van den Broek). 
 
High expression levels of iNOS correlated with reduced tumor stage, suggesting that when 
macrophages are recruited to developing tumors, TAMs display an M1 phenotype. We detected 
a low expression level of IL-10 and FoxP3 in small tumors that increased with tumor progression. 
Additionally, high levels of M2-associated genes correlated with increased tumor stage, 
suggesting the establishment of an immunoregulatory milieu during tumor progression, which is 
characterized by elevated levels of IL-10, increased presence of Tregs and a phenotype switch of 
M1 towards M2 TAMs. Tumor cells at least partially contribute to this switch. Immunosuppressive 
factors of the tumor microenvironment, including M2 TAMs, impact on the cytokine profile of T 
cells leading to reduced production of effector cytokines and increased secretion of IL-10. 
Furthermore we detected an increased expression of immunoregulatory molecules on T cells 
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from TILs, which is a sign for exhaustion of T cells within tumors. Another hint for the impaired 
function of T cells might be that we were not able to detect TAA-specific T cell responses in TILs 
despite the detection of TAA-specific T cell responses in 85% of PBMCS as observed in the case 
of CCND1. Finally, the increased presence of TAMs also correlated with an increased incidence 
of metastasis, suggesting an impact of TAMs in promoting ccRCC spread. Significant correlation 
of high iNOS levels with increased survival time and a significant correlation of CD68 and M2-like 
markers with reduced survival strengthen the point that TAMs influence disease outcome in 
ccRCC patients. 
 
Based on the above, different therapeutic tools can be designed to target the immunoregulatory 
milieu that might improve standard and immunotherapy for ccRCC patients. 
Cytokine-based immunotherapy is so far the only treatment option for metastatic ccRCC that was 
shown to result in few complete responses (195, 196). However, high-dose IL-2 treatment is very 
toxic, can be only administered to a selected group of patients and in most of the cases the long-
term effect is not achieved (197). One explanation for this might be the increased presence of 
Tregs in ccRCC patients receiving IL-2-based immunotherapy (198). Like activated T cells also 
Tregs express the IL-2 receptor (IL-2R), therefore not only effector T cells are stimulated to 
proliferate, but also Tregs. The fact that increased levels of FoxP3, the transcription factor 
specific for Tregs, correlated with reduced survival, and because of the immunosuppressive 
functions of Tregs, depletion of these cells might be one possibility to improve anti-tumor 
immunity and thus patient outcome. Tregs express high levels of CD25, a subunit of the IL-2R on 
the surface. Targeting CD25 by using depleting mAbs or an IL-2-diphteria toxin fusion protein 
was shown to enhance anti-tumor immune responses (199, 200). However, no striking effects 
were observed so far, eventually because the lack of specificity in that also activated T cells 
express CD25 and might be depleted along the way (201). The IL-2-diphteria toxin fusion protein 
denileukin diftitox in combination with high dose IL-2 showed promising results in a phase I study 
of patients with metastatic RCC (202). The use of IL-2/anti-IL-2 immune complexes may increase 
efficacy and reduce toxicity at the same time (203). Such effects were observed with human IL-2 
in complex with the human-IL-2-specific antibody MAB602 in mice, but it still has to be defined 
whether these complexes have comparable functions in humans. Blocking CTLA-4 is another 
way to target Tregs and was shown to result in the enhanced recruitment of memory T cells in 
metastatic melanoma (204). In one study, treatment with the CTLA-4 antibody ipilimumab 
revealed partial response in 5 of 40 patients with metastatic RCC (205). High dose IL-2 in 
combination with CTLA-4 blockage revealed promising results in patients with metastatic 
melanoma (206). Since also high dose IL-2 cytokine therapy shows some effect in ccRCC 
patients, the combination of high-dose IL-2 with CTLA-4 antibodies might be one strategy to 
improve outcome of cytokine-based immunotherapy for those patients. 
As described before, CTLA-4 is not only expressed on Tregs, but also on effector T cells where 
its interaction with CD28 on APCs leads to an inhibition of the T cell response. Besides 
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antibodies blocking CTLA-4, there are other novel immune-modulating antibodies under 
investigation that target co-stimulatory signals involved in T cell activation. As seen in Figure D-3 
there are several immune checkpoints that can be targeted either with agonistic antibodies 
stimulating the signaling of activating receptors or with blocking antibodies that suppress the 
signaling of inhibitory receptors (17). In this study here we saw an increased expression of CTLA-
4, PD-1 and also Tim-3 in TILs and thus these molecules might be interesting therapeutic targets 
in ccRCC. 
 
 
 
Figure D-3: T cell targets for immunoregulatroy antibody therapy 
Summary of activating and inhibitory receptors on activated T cells that can be targeted by 
antibody-mediated immunotherapy (17).  
 
 
Our results suggest that macrophages play a central role in the local immunoregulation during 
ccRCC development and hence targeting TAMs might present a potential strategy to control 
tumor growth. Unspecific depletion of TAMs can be achieved by for example the administration of 
bisphosphonate clodronic acid. This treatment reduced microvascular density and tumor growth 
in a mouse model of RCC (RENCA) (207). Also the monoclonal antibody bevacizumab, known to 
inhibit VEGF-A, a chemoattractant for macrophages, was shown to block macrophage 
recruitment in different tumor mouse models thereby inhibiting tumor growth (208, 209). 
Depending on their polarization TAMs can either promote tumor progression or tumor rejection 
via activation or suppression of various subsets of effector and regulatory immune cells.  
Therefore, instead of macrophage depletion, re-orientation of the tumor-promoting phenotype of 
TAMs into the anti-tumoral phenotype sounds promising although technically very challenging. 
Several studies in mice demonstrate that re-polarization of TAMs is possible. Treatment with the 
M1-associated cytokine IL-12 altered the functional activity of TAMs from a tumor-promoting 
profile to a proinflammatory profile and inhibited tumor growth in the RENCA mouse model (210, 
211). Furthermore, TAMs lacking STAT-6, the mediator of IL-4 and IL-13 signaling, display a M1 
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phenotype with high levels of NO, leading to spontaneous rejection of mammary carcinoma in 
mice (212). IL-10 was observed to increase during tumor progression and is known to induce an 
M2-like phenotype in TAMs. Since IL-10 has many other immunoregulatory functions, like 
impairing the antigen-presentation capabilities of APCs, thereby inhibiting T cell proliferation 
(213), neutralizing IL-10 could be another immunotherapeutic strategy to induce M2 to M1 
polarization and to increase anti-tumor immunity. In this regard, the combination of CpG and anti-
IL10 receptor antibodies was shown to induce a switch from M2 to M1 with a reduction in tumor 
size (214, 215), and also the inhibition of STAT-3 activity, required for IL-10 biological functions, 
restored the M1-related functions in TAMs and revealed tumor inhibition (216). 
It was shown that PD-1 ligation induces IL-10 production by monocytes leading to an inhibition of 
CD4+ T cell responses (217). We saw an increased expression of PD-1 on TILs and also 
elevated levels of PD-L1 on M2 TAMs suggesting that also in ccRCC tumors the impact of TAMs 
on T cells might be mediated trough PD-1/PD-L1 interactions. Thus, blockade of either PD-1 or 
PD-L1 might represent one possibility to overcome immunosuppression. Indeed, an antibody 
blocking PD-1 was recently tested in different cancers in a clinical trial (218) that resulted in an 
objective response in 27% (9/33) of RCC patients (219). 
 
To date, the clinical evaluation of immunotherapy has mainly focused on single agents that 
interfere with individual steps in the anti-tumor immune response. However, it is becoming clear 
that monotherapies are unlikely to be sufficiently effective (220). Instead, targeting of multiple 
pathways and processes may be necessary. These include (i) the induction of immunogenic cell 
death through radiotherapy (221) chemotherapy (222), or targeted therapy such as kinase 
inhibitors (223), plus (ii) improving antigen presentation (224) including upregulation of co-
stimulatory signals (24), plus (iii) blocking immune checkpoints of T cell activation, or regulatory 
cell types. 
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5.  APPENDIX 
 
5.1  Functional differences of peripheral and local T cells in patients with ccRCC 
 
Despite detection of Cyclin D1 (CCND1)-specific CD8+ T cells in PBMCs and corresponding TILs 
of ccRCC patients (results part 2.1) we only observed T cell responses towards CCND1-peptide 
simulation in PBMCs but not in TILs. Therefore, we were not able to compare TAA-specific 
responses of PBMCs and TILs. To at least enable a comparison of the function of TILs and 
PBMCs to some extent, we decided to stimulate isolated T cells polyclonally instead of antigen-
specifically. In this regard, we FACS sorted CD45RA- T cells from PBMCs and autologous TILs 
and assessed their cytokine profile after TCR-dependent and -independent ex-vivo polyclonal 
stimulation using anti-CD3/CD28 beads and PMA plus ionomycin respectively (Figure A-1). 
These assays were performed on the same patient material that was used for functional studies 
in results part 2.2. 
CD8+ TILs secreted significantly less TNF- than CD8+ PBMCs after TCR-dependent stimulation 
and showed a tendency to secrete less IL-2 and IFN- after both stimulation procedures. 
Furthermore, CD8+ TILs produced significantly more IL-10, and there was a trend towards 
increased secretion of TGF- after TCR-dependent and -independent stimulation. In the same 
line CD4+ TILs also produced less IL-2 after TCR-independent stimulation compared to CD4+ 
PBMCs and more IL-10 after both stimulation methods. However, significantly more IFN- was 
produced by CD4+ TILs after both stimulation procedures and also significantly more TNF- after 
TCR-dependent stimulation. Attig et al. also reported that T cells from ccRCC TILs are able to 
respond to both TCR-dependent and -independent stimulations and they noted that TILs 
produced more effector and also more regulatory cytokines than corresponding PBMCs (1). The 
observation in our study that CD4+ TILs show an increased secretion of effector cytokines IFN- 
and TNF-, but a reduced production of IL-2, suggests that CD4+ TILs are in general able to 
respond to stimulations, however don’t exert the complete repertoire of all effector cytokines 
needed for a proper anti-tumor immune response. IL-2 produced by CD4+ T cell is for example 
required for expansion and survival of CD8+ T cells (2). From these results we conclude that the 
function of T cells infiltrating ccRCC tumors differs to some extent from T cells in the periphery. 
CD8+ TILs were not able to secrete as much of the effector cytokines as PBMCs, and also CD4+ 
TILs produced less IL-2. Both CD4+ and CD8+ TILs produced more of the regulatory cytokine IL-
10 thereby contributing to the immunosuppressive milieu in ccRCC tumors. Even though the 
production of IL-10 is more linked to CD4+ T cells, and Tregs (3) it was shown that also CD8+ T 
cells are a source of IL-10 within tumors (1, 4). 
Furthermore, when comparing the phenotype of T cells from TILs and corresponding PBMCs in 
regard to the expression of regulatory molecules we observed a difference towards a more 
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regulated phenotype of TILs (Figure 4 and 5 in results 2.2). While we saw an increased 
expression of TGF-, IL-17, IL-4, IL-13 and also of IL-2 on the mRNA level of sorted non-
stimulated CD4+ TILs compared to PBMCs (Figure 4 in results 2.2), they did not secrete more 
of these cytokines after polyclonal stimulations compared to PBMCs (Figure A-1). While mRNA 
analysis was possible ex-vivo directly after FACS sorting, T cells had to be cultured for 
stimulation experiments. T cells after culture might not reflect the exact situation as observed 
directly after FACS sorting what might explain the discrepancy between mRNA and protein levels 
(5). However, that T cells express high levels of cytokines on the mRNA level, but are not able to 
produce the cytokine on the protein level was observed before for self-reactive T cells, and it was 
suggested that translation is limited due to posttranscriptional silencing (6). The fact that we 
observed an increased secretion of TGF- and IL-4 when CD4+ T cells were stimulated in 
presence of the tumor microenvironment and TAMs (Figure 6 and 7 in results 2.2), might as 
well suggest that the disconnect in mRNA and protein level observed in our study is due to an 
altered behavior of T cells when cultured and stimulated isolated from the tumor 
microenvironment since then they are not under the influence of immunoregulatory mediators like 
TAMs anymore. 
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Figure A-1: Cytokine profile differs between T cells from PBMCs and TILs 
Intracellular staining for cytokines is shown for ViViD-CD45RA-CD4+ T cells (A) and ViViD-
CD45RA-CD8+ T cells (B). Each symbol represents an individual patient. Results of PBMCs and 
TILs from the same patient are connected by a thin line. Wilcoxon matched-pairs signed rank test 
was used to analyze statistical significance between groups (GraphPad Prism Software). Means 
of each group and significant differences are depicted (* p<0.05; ** p<0.005). 
Methodological details can be found in materials and methods section of results part 2.2. Shortly 
T cells were FACS sorted from TILs and PBMCs of the same patient and ex-vivo stimulated with 
anti-CD3/CD28 Dynabeads (ratio T cells:beads 1:3) or with PMA plus ionomycin for 6 h at 37 °C 
in the presence of Brefeldin A. Subsequently, cells were surface stained with a pooled 
fluorochrom-conjugated antibody cocktail (CD4+ T cells: CD45 KromeOrange, CD4 FITC, with 
(a1) or without TGF- PE (a2), and CD8+ T cells: CD45 KromeOrange, CD8 ECD (b)) including 
live-dead staining (LIVE/DEAD® Fixable Violet Dead Cell Stain Kit (ViViD), Invitrogen) in PBS for 
20 min at room temperature in the dark. Intracellular staining was performed with a mix of 
fluorescent-conjugated antibodies (IL-2 PerCPCy5.5, IL-10 APC, IFN- Alexa700 (a1); IL17 PE, 
IL4 PECy7, IL13 APC, TNF- PerCPCy5.5 (a2); TNF- PerCPCy5.5, IL-2 PECy7, IL-10 APC, 
IFN- Alexa700 (b)) in permeabilization buffer for 20 min at room temperature in the dark. 
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5.2  Correlation of immune response-related genes in ccRCC tumor material 
 
Recent efforts have made progress in using formalin-fixed paraffin-embedded (FFPE) tissues for 
molecular analysis, enabling studies on enormous archives of existing specimens (1), especially 
in regard to long-term patient survival. Quantitative real-time PCR (qRT-PCR), using TaqMan® 
Gene expression assays, is a sensitive, accurate and highly reproducible method to study gene 
expression in FFPE material (2-4). Furthermore, qRT-PCR precisely determines cell density and 
cytokine gene profile in the tumor microenvironment (5). Based on these findings, we performed 
a retrospective qRT-PCR screen, using TaqMan® Gene expression assays for 43 different target 
genes related to tumor immunology (Supplemental Table S1A, B in results 2.2) on FFPE 
material of ccRCCs from 54 patients (Supplemental Table S2 in results 2.2). To receive 
sufficient template for complete analyses cDNA had to be preamplified prior to qRT-PCR 
performance. Preamplification of cDNA was introduced before as a suitable method for 
amplification of limited cDNA of FFPE material (6). Significant correlation of mRNA levels from 
non-preamplified cDNA and preamplified cDNA confirmed that preamplification was carried out 
uniformly among all samples (Supplementary Figure S3 in results 2.2). Correlations between 
the expression levels of different target genes were analyzed using the Spearman’s Rho 
correlation test. Table A-1 A and B summarizes the results of the Spearman’s Rho correlation 
test on data received from an initial qRT-PCR screen on non-preamplified cDNA and Table A-2 
A and B the results on data from the additional screen on preamplified cDNA. 
Expression levels of the pan-macrophage marker CD68 correlated significantly with genes of an 
inflammatory signature including LT-R, MHC-class II, MHC-class I, CD4, HVEM (Table A-1) 
and also IRF-5 (Table A-2). Furthermore, CD68 expression levels also correlated with the type 2 
response-related gene TGF- (Table A-1) and also FN-1 (Table A-2). Together with the fact that 
enhanced CD68 mRNA levels strongly correlate with increased incidence of metastasis and 
reduced survival (Figure 3B and 1A in results 2.2), CD68+ TAMs seem to mediate tumor-
promoting inflammation in the case of ccRCC.  
Despite being a marker for M1 macrophages, for iNOS and the production of NO multiple data 
was published, on the one hand providing evidence for a pro-apoptotic role and a relation with 
favorable prognosis, and on the other hand providing evidence for a role in tumor promotion (7). 
Here the levels of iNOS negatively correlate with the M2-related genes IL-10 (Table A-1) and 
CD163 (Table A-2) and show an association with the inflammation-related genes LT-R and 
HVEM (Table A-1). Together with the observation that increased levels of iNOS correlate with 
prolonged survival and low tumor stage (Figure 1B and 3C in results 2.2), we suggest that 
iNOS is indeed a marker for M1 TAMs in ccRCC, where it has an effector function in anti-tumor 
immunity.  
Another molecule found on antigen-presenting cells with dual roles in anti-tumor immunity is 
HVEM. By binding the receptor LIGHT it promotes T cell effector functions and by binding the 
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BTLA receptor inhibition of T cell responses (8). We observed a negative correlation of HVEM 
with the M2-related genes IL-10 and CD163 and a positive correlation with the inflammation-
related genes LT-R and iNOS (Table A-1). Accordingly, increased mRNA levels of HVEM 
showed a tendency to correlate with increased survival (Supplementary Figure S1A in results 
2.2). Furthermore, no difference in the inhibitory receptor BTLA in T cells from PBMCs and TILs 
was observed (Figure 4 in results 2.2) suggesting that the anti-tumor effects of HVEM are 
prominent in ccRCC. 
An association of Th1 type responses and favorable prognosis was observed in many cancer 
types including ccRCC (9, 10). Th1 cells can drive classical activation of M1 macrophages by 
producing IFN-. M1 macrophages start to express cytokines and chemokines, including IL-12, 
CXCL9 and CXCL10 leading to the recruitment of Th1 cells and the amplification of a type 1 
response (11, 12). In this line, we could correlate increased expression levels of the M1 marker 
iNOS with prolonged survival (Figure 1B in results 2.2) and in the same tumor samples also a 
similar trend for the expression levels of the effector cytokines TNF- and perforin 
(Supplementary Figure S1A in results 2.2).  
On the other hand we observed a significant correlation of FoxP3 with reduced survival (Figure 
1A in results 2.2) as already published for different cancer types including ccRCC (9, 13, 14). A 
similar trend we also observed for CTLA-4 and IL-10 (Supplementary Figure S1B in results 
2.2). We found FoxP3 and IL-10 transcript levels increased in late-stage tumors (Supplementary 
Figure S7 in results 2.2). In this line, Table A-2 illustrates that IL-10 transcript levels correlate 
with the M2 markers CD163 and MR and show a tendency to negatively correlate with 
inflammation-related genes such as HVEM, LT-R and the M1-signature genes iNOS (Table A-
1) and IRF-5 (Table A-2). Furthermore, FoxP3 positively correlates with CTLA-4, PD-1, PD-L1 
and CD200 and to some extend also with Tim-3 (Table A-1), all molecules known to have a role 
in dampening T cell responses. 
We found a significant correlation of CD163 expression with other M2-associated genes like IL-
10, MR and FN-1 (Table A-2) and on the other hand, a significant negative correlation with CD3, 
the Th1 cytokine IFN- (Table A-1) and the M1 marker iNOS (Table A-2). These findings and the 
fact that CD163 shows an association with reduced survival and increased pT (Figure 1B and 
3C in results 2.2) suggest that CD163 expression levels are indeed a sign of tumor-promoting 
M2 TAMs in ccRCC. 
A positive feedback loop between tumor cells and TAMs, involving EGF, CSF-1, their receptors 
and Mena, was suggested to promote metastasis (15). To test whether this mechanism plays a 
role in ccRCC, we also included those genes in the survival and correlation analysis. After 
normalization to the levels of CD45, we found a significant correlation of the macrophage-
associated genes EGF and CSF1R with CD68 (Table A-2). It was more problematic to analyze 
the tumor-associated genes EGFR and CSF-1 and Mena, because we lacked a control gene that 
would normalize to the amount of tumor cells. When normalized for PPIA or CD45, a correlation 
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was observed toward increased levels of Mena and reduced survival (Supplementary Figure 
S1C in results 2.2). Furthermore, PPIA-normalized levels of Mena correlated with increased 
levels of CSF1-R and CD163, as well as with reduced levels of IL12 (Table A-2), supporting the 
idea that Mena is involved in M2 TAM-mediated promotion of metastasis. Because of the lack of 
a suitable normalization control, the results are not definite and it is not possible to draw any 
conclusions in whether this pathway plays a role in TAM-mediated metastasis in ccRCC. 
In summary we found that in tumor samples of ccRCC patients transcripts related to Th1 cells 
followed a similar expression pattern than transcripts related to M1 TAMs. Expression levels of 
these genes negatively correlated with transcripts related to Th2, inhibitory molecules and M2 
TAMs. In combination with the fact that we observed a significant positive correlation of the M1 
marker iNOS and patient survival and the opposite for FoxP3 and M2-related genes, suggests 
that Th1 responses and M1 TAMs are important for anti-tumor immune responses in ccRCC 
patients, while Th2 responses, inhibitory molecules and M2 TAMs negatively impact on that. 
Hence, immunotherapy for ccRCC should be designed to stimulate Th1 responses and M1 
TAMs, and ideally simultaneously suppress Th2 responses, inhibitory molecules and M2 TAMs. 
 
APPENDIX 
105 
 
Table A-1A: Summary of correlations between target genes of the initial qRT-PCR screen on 
non-preamplified cDNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of correlations between target gene expression levels within FFPE ccRCC samples are 
shown after normalization to the Ct values of CD45. Correlations were statistically analyzed using 
the Spearman’s Rho correlation test. Tendencies (p<0.1) are marked with (x), significant 
correlations with x (p<0.05) and with xx (p<0.01), inverse tendencies and correlations are 
highlighted in red. 
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Table A-2A: Summary of correlations between target genes of the supplemental qRT-PCR 
analysis on preamplified cDNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Summary of correlations between target gene expression levels within FFPE ccRCC samples are 
shown after normalization to the Ct values of CD45 or, when mentioned, to PPIA. Correlations 
were statistically analyzed using the Spearman’s Rho correlation test. Tendencies (p<0.1) are 
marked with (x), significant correlations with x (p<0.05) and with xx (p<0.01), inverse tendencies 
and correlations are highlighted in red. 
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Table A-1B: Statistical values of correlations between target genes of the initial qRT-PCR screen 
on non-preamplified cDNA 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
IL10 IFNg TNFa LTb MICA PD1 PDL1 FoxP3 CTLA4 IDO Perforin GranzymeB iNOS MICB
Correlation 
Coefficient
1,000 -,117 -,160 ,040 -,134 -,065 ,019 ,197 ,258 -,158 -,217 -,022 -.316* ,037
Sig. (2-tailed) ,399 ,248 ,773 ,333 ,638 ,893 ,154 ,059 ,255 ,115 ,877 ,020 ,790
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,117 1,000 -,045 ,244 ,041 .644** ,188 .303* ,243 ,017 ,170 ,197 -,225 ,047
Sig. (2-tailed) ,399 ,746 ,076 ,770 ,000 ,173 ,026 ,077 ,903 ,219 ,153 ,102 ,733
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,160 -,045 1,000 ,238 ,226 -,092 ,164 -,053 ,075 .297* .312* ,137 ,006 ,164
Sig. (2-tailed) ,248 ,746 ,083 ,101 ,507 ,235 ,704 ,587 ,029 ,022 ,323 ,966 ,237
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,040 ,244 ,238 1,000 ,249 ,220 .278* .417** ,217 -,025 ,191 -,002 ,181 ,000
Sig. (2-tailed) ,773 ,076 ,083 ,069 ,111 ,042 ,002 ,114 ,860 ,167 ,990 ,190 ,997
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,134 ,041 ,226 ,249 1,000 ,031 .450
**
.293
* ,150 -,016 .295
* ,118 .270
* ,174
Sig. (2-tailed) ,333 ,770 ,101 ,069 ,824 ,001 ,031 ,280 ,911 ,030 ,397 ,048 ,209
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,065 .644
** -,092 ,220 ,031 1,000 ,140 .467
** ,040 ,034 .311
*
.299
* -,127 ,062
Sig. (2-tailed) ,638 ,000 ,507 ,111 ,824 ,312 ,000 ,773 ,809 ,022 ,028 ,360 ,654
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,019 ,188 ,164 .278
*
.450
** ,140 1,000 .523
**
.403
** ,183 ,195 ,137 .296
*
.373
**
Sig. (2-tailed) ,893 ,173 ,235 ,042 ,001 ,312 ,000 ,003 ,186 ,157 ,325 ,030 ,005
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,197 .303
* -,053 .417
**
.293
*
.467
**
.523
** 1,000 .399
** ,137 ,060 ,046 ,076 .311
*
Sig. (2-tailed) ,154 ,026 ,704 ,002 ,031 ,000 ,000 ,003 ,324 ,667 ,739 ,585 ,022
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,258 ,243 ,075 ,217 ,150 ,040 .403
**
.399
** 1,000 ,149 -,145 ,205 ,088 ,203
Sig. (2-tailed) ,059 ,077 ,587 ,114 ,280 ,773 ,003 ,003 ,283 ,296 ,138 ,527 ,141
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,158 ,017 .297
* -,025 -,016 ,034 ,183 ,137 ,149 1,000 .322
*
.360
** -,021 ,219
Sig. (2-tailed) ,255 ,903 ,029 ,860 ,911 ,809 ,186 ,324 ,283 ,018 ,008 ,881 ,111
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,217 ,170 .312
* ,191 .295
*
.311
* ,195 ,060 -,145 .322
* 1,000 .547
** ,097 ,138
Sig. (2-tailed) ,115 ,219 ,022 ,167 ,030 ,022 ,157 ,667 ,296 ,018 ,000 ,484 ,320
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,022 ,197 ,137 -,002 ,118 .299
* ,137 ,046 ,205 .360
**
.547
** 1,000 ,030 ,130
Sig. (2-tailed) ,877 ,153 ,323 ,990 ,397 ,028 ,325 ,739 ,138 ,008 ,000 ,831 ,350
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-.316
* -,225 ,006 ,181 .270
* -,127 .296
* ,076 ,088 -,021 ,097 ,030 1,000 ,199
Sig. (2-tailed) ,020 ,102 ,966 ,190 ,048 ,360 ,030 ,585 ,527 ,881 ,484 ,831 ,149
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,037 ,047 ,164 ,000 ,174 ,062 .373
**
.311
* ,203 ,219 ,138 ,130 ,199 1,000
Sig. (2-tailed) ,790 ,733 ,237 ,997 ,209 ,654 ,005 ,022 ,141 ,111 ,320 ,350 ,149
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,075 ,030 .321
* ,220 ,206 ,149 .353
**
.318
*
.306
* ,105 ,196 ,180 ,180 ,165
Sig. (2-tailed) ,589 ,831 ,018 ,110 ,134 ,283 ,009 ,019 ,024 ,452 ,155 ,194 ,194 ,233
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,207 ,055 ,113 ,061 .557
** ,217 .302
* ,262 -,037 -,085 ,115 -,106 ,260 ,193
Sig. (2-tailed) ,134 ,691 ,418 ,662 ,000 ,114 ,026 ,056 ,788 ,543 ,406 ,447 ,058 ,161
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-.306
* -,113 ,203 ,105 .603
** -,008 .393
** ,249 -,068 ,001 ,076 -,101 .296
*
.364
**
Sig. (2-tailed) ,024 ,417 ,141 ,450 ,000 ,952 ,003 ,070 ,623 ,996 ,583 ,467 ,030 ,007
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,101 -,077 .345
* ,217 .539
** -,011 ,245 ,017 ,096 ,005 .285
* -,037 ,068 -,100
Sig. (2-tailed) ,467 ,581 ,011 ,116 ,000 ,938 ,075 ,905 ,491 ,971 ,036 ,791 ,624 ,474
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-.290
* ,100 ,072 ,016 .305
* ,257 .311
*
.308
* -,256 -,044 ,165 -,116 ,042 .370
**
Sig. (2-tailed) ,033 ,471 ,603 ,907 ,025 ,061 ,022 ,024 ,062 ,754 ,234 ,405 ,763 ,006
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-.301
* ,100 -,068 -,153 ,258 ,261 ,153 .360
** -,160 ,072 ,014 -,180 ,051 .281
*
Sig. (2-tailed) ,027 ,472 ,624 ,269 ,060 ,057 ,269 ,007 ,248 ,603 ,919 ,192 ,716 ,040
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,033 .407
** -,035 ,225 -,267 .546
** -,157 ,122 -,151 ,025 .424
**
.277
* -,009 -,026
Sig. (2-tailed) ,814 ,002 ,801 ,102 ,051 ,000 ,256 ,378 ,277 ,860 ,001 ,043 ,951 ,851
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,172 .607
** -,129 ,219 -,147 .763
** ,053 .328
* ,016 -,068 .288
* ,154 ,021 ,039
Sig. (2-tailed) ,212 ,000 ,353 ,111 ,288 ,000 ,704 ,015 ,911 ,627 ,035 ,265 ,878 ,780
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,178 .613
** -,133 ,131 -,222 .721
** -,066 .294
* -,157 -,002 .280
* ,263 -,135 ,111
Sig. (2-tailed) ,197 ,000 ,339 ,346 ,106 ,000 ,637 ,031 ,256 ,991 ,040 ,055 ,329 ,425
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,029 ,052 ,188 ,234 .498
** ,204 .360
**
.351
** ,022 ,201 ,251 ,052 ,214 .333
*
Sig. (2-tailed) ,833 ,709 ,173 ,088 ,000 ,138 ,008 ,009 ,872 ,145 ,067 ,710 ,120 ,014
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
.415
**
-.381
** -,068 -,219 ,029 -.320
* -,056 -,063 ,120 ,056 -,094 -,064 ,084 -,113
Sig. (2-tailed) ,002 ,004 ,625 ,111 ,836 ,018 ,687 ,649 ,389 ,689 ,499 ,647 ,548 ,416
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,157 ,061 ,154 -,024 .435
** ,019 ,150 ,169 -,020 -,219 ,165 -,180 -,099 ,154
Sig. (2-tailed) ,257 ,661 ,267 ,862 ,001 ,894 ,281 ,223 ,887 ,112 ,233 ,194 ,477 ,265
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-.344
* -,034 ,256 ,246 .502
** ,054 .453
** ,201 -,043 ,047 ,253 -,047 .334
*
.328
*
Sig. (2-tailed) ,011 ,809 ,062 ,073 ,000 ,697 ,001 ,144 ,758 ,734 ,064 ,735 ,013 ,015
N 54 54 54 54 54 54 54 54 54 54 54 54 54 54
*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
CD163
CD68
HVEM
MHCI
CD200
NKG2D
CD8
CD3
CD4
MICB
Tim3
TGFb
LTbR
MHCII
CTLA4
IDO
Perforin
GranzymeB
iNOS
Spearman's rho IL10
IFNg
TNFa
LTb
MICA
PD1
PDL1
FoxP3
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Statistical values of correlations between target gene expression levels within FFPE ccRCC 
samples are shown after normalization to the Ct values of CD45. Correlations were statistically 
analyzed using the Spearman’s Rho correlation test. 
 
 
Tim3 TGFb LTbR MHCII MHCI CD200 NKG2D CD8 CD3 CD4 CD163 CD68 HVEM
Correlation 
Coefficient
-,075 -,207 -.306
* -,101 -.290
*
-.301
* ,033 -,172 -,178 ,029 .415
** -,157 -.344
*
Sig. (2-tailed) ,589 ,134 ,024 ,467 ,033 ,027 ,814 ,212 ,197 ,833 ,002 ,257 ,011
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,030 ,055 -,113 -,077 ,100 ,100 .407
**
.607
**
.613
** ,052 -.381
** ,061 -,034
Sig. (2-tailed) ,831 ,691 ,417 ,581 ,471 ,472 ,002 ,000 ,000 ,709 ,004 ,661 ,809
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
.321
* ,113 ,203 .345
* ,072 -,068 -,035 -,129 -,133 ,188 -,068 ,154 ,256
Sig. (2-tailed) ,018 ,418 ,141 ,011 ,603 ,624 ,801 ,353 ,339 ,173 ,625 ,267 ,062
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,220 ,061 ,105 ,217 ,016 -,153 ,225 ,219 ,131 ,234 -,219 -,024 ,246
Sig. (2-tailed) ,110 ,662 ,450 ,116 ,907 ,269 ,102 ,111 ,346 ,088 ,111 ,862 ,073
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,206 .557
**
.603
**
.539
**
.305
* ,258 -,267 -,147 -,222 .498
** ,029 .435
**
.502
**
Sig. (2-tailed) ,134 ,000 ,000 ,000 ,025 ,060 ,051 ,288 ,106 ,000 ,836 ,001 ,000
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,149 ,217 -,008 -,011 ,257 ,261 .546
**
.763
**
.721
** ,204 -.320
* ,019 ,054
Sig. (2-tailed) ,283 ,114 ,952 ,938 ,061 ,057 ,000 ,000 ,000 ,138 ,018 ,894 ,697
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
.353
**
.302
*
.393
** ,245 .311
* ,153 -,157 ,053 -,066 .360
** -,056 ,150 .453
**
Sig. (2-tailed) ,009 ,026 ,003 ,075 ,022 ,269 ,256 ,704 ,637 ,008 ,687 ,281 ,001
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
.318
* ,262 ,249 ,017 .308
*
.360
** ,122 .328
*
.294
*
.351
** -,063 ,169 ,201
Sig. (2-tailed) ,019 ,056 ,070 ,905 ,024 ,007 ,378 ,015 ,031 ,009 ,649 ,223 ,144
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
.306
* -,037 -,068 ,096 -,256 -,160 -,151 ,016 -,157 ,022 ,120 -,020 -,043
Sig. (2-tailed) ,024 ,788 ,623 ,491 ,062 ,248 ,277 ,911 ,256 ,872 ,389 ,887 ,758
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,105 -,085 ,001 ,005 -,044 ,072 ,025 -,068 -,002 ,201 ,056 -,219 ,047
Sig. (2-tailed) ,452 ,543 ,996 ,971 ,754 ,603 ,860 ,627 ,991 ,145 ,689 ,112 ,734
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,196 ,115 ,076 .285
* ,165 ,014 .424
**
.288
*
.280
* ,251 -,094 ,165 ,253
Sig. (2-tailed) ,155 ,406 ,583 ,036 ,234 ,919 ,001 ,035 ,040 ,067 ,499 ,233 ,064
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,180 -,106 -,101 -,037 -,116 -,180 .277
* ,154 ,263 ,052 -,064 -,180 -,047
Sig. (2-tailed) ,194 ,447 ,467 ,791 ,405 ,192 ,043 ,265 ,055 ,710 ,647 ,194 ,735
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,180 ,260 .296
* ,068 ,042 ,051 -,009 ,021 -,135 ,214 ,084 -,099 .334
*
Sig. (2-tailed) ,194 ,058 ,030 ,624 ,763 ,716 ,951 ,878 ,329 ,120 ,548 ,477 ,013
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,165 ,193 .364
** -,100 .370
**
.281
* -,026 ,039 ,111 .333
* -,113 ,154 .328
*
Sig. (2-tailed) ,233 ,161 ,007 ,474 ,006 ,040 ,851 ,780 ,425 ,014 ,416 ,265 ,015
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
1,000 ,118 ,156 .379
** ,114 ,018 -,013 ,124 ,028 ,136 -,136 ,188 .278
*
Sig. (2-tailed) ,394 ,261 ,005 ,411 ,896 ,928 ,371 ,839 ,328 ,328 ,174 ,042
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,118 1,000 .671
**
.364
**
.513
**
.430
** -,065 ,164 ,013 .418
** -,085 .574
**
.521
**
Sig. (2-tailed) ,394 ,000 ,007 ,000 ,001 ,641 ,237 ,926 ,002 ,541 ,000 ,000
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,156 .671
** 1,000 .355
**
.566
**
.501
** -,189 -,064 -,049 .521
** -,029 .595
**
.672
**
Sig. (2-tailed) ,261 ,000 ,008 ,000 ,000 ,172 ,648 ,726 ,000 ,835 ,000 ,000
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
.379
**
.364
**
.355
** 1,000 ,161 -,066 -,177 -,112 -,228 .434
** -,032 .510
**
.468
**
Sig. (2-tailed) ,005 ,007 ,008 ,245 ,637 ,200 ,420 ,097 ,001 ,821 ,000 ,000
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,114 .513
**
.566
** ,161 1,000 .657
** ,127 ,204 ,257 .401
**
-.317
*
.485
**
.546
**
Sig. (2-tailed) ,411 ,000 ,000 ,245 ,000 ,360 ,138 ,061 ,003 ,020 ,000 ,000
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,018 .430
**
.501
** -,066 .657
** 1,000 -,030 ,157 ,194 .276
* -,105 .343
*
.291
*
Sig. (2-tailed) ,896 ,001 ,000 ,637 ,000 ,828 ,257 ,160 ,043 ,451 ,011 ,033
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,013 -,065 -,189 -,177 ,127 -,030 1,000 .674
**
.705
** ,086 -,090 -,167 -,057
Sig. (2-tailed) ,928 ,641 ,172 ,200 ,360 ,828 ,000 ,000 ,535 ,520 ,226 ,681
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,124 ,164 -,064 -,112 ,204 ,157 .674
** 1,000 .726
** -,030 -.330
* -,031 ,022
Sig. (2-tailed) ,371 ,237 ,648 ,420 ,138 ,257 ,000 ,000 ,827 ,015 ,822 ,873
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,028 ,013 -,049 -,228 ,257 ,194 .705
**
.726
** 1,000 ,107 -.461
** -,082 ,047
Sig. (2-tailed) ,839 ,926 ,726 ,097 ,061 ,160 ,000 ,000 ,441 ,000 ,556 ,738
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,136 .418
**
.521
**
.434
**
.401
**
.276
* ,086 -,030 ,107 1,000 ,195 .391
**
.399
**
Sig. (2-tailed) ,328 ,002 ,000 ,001 ,003 ,043 ,535 ,827 ,441 ,159 ,003 ,003
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
-,136 -,085 -,029 -,032 -.317
* -,105 -,090 -.330
*
-.461
** ,195 1,000 -,029 -.331
*
Sig. (2-tailed) ,328 ,541 ,835 ,821 ,020 ,451 ,520 ,015 ,000 ,159 ,835 ,015
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
,188 .574
**
.595
**
.510
**
.485
**
.343
* -,167 -,031 -,082 .391
** -,029 1,000 .450
**
Sig. (2-tailed) ,174 ,000 ,000 ,000 ,000 ,011 ,226 ,822 ,556 ,003 ,835 ,001
N 54 54 54 54 54 54 54 54 54 54 54 54 54
Correlation 
Coefficient
.278
*
.521
**
.672
**
.468
**
.546
**
.291
* -,057 ,022 ,047 .399
**
-.331
*
.450
** 1,000
Sig. (2-tailed) ,042 ,000 ,000 ,000 ,000 ,033 ,681 ,873 ,738 ,003 ,015 ,001
N 54 54 54 54 54 54 54 54 54 54 54 54 54
IDO
Spearman's rho IL10
IFNg
TNFa
LTb
MICA
PD1
PDL1
FoxP3
CTLA4
CD8
Perforin
GranzymeB
iNOS
MICB
Tim3
TGFb
LTbR
MHCII
MHCI
CD200
NKG2D
CD3
CD4
CD163
CD68
HVEM
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Table A-2B: Statistical values of correlations between target genes of the supplemental qRT-
PCR analysis on preamplified cDNA 
 
CD68 MHCII CD163 MR IRF4 FN1 IL10 IRF5 TNFa iNOS
Correlation 
Coefficient
1.000 .470
** .086 -.011 -.112 .393
** -.091 .563
** .276 .112
Sig. (2-tailed) .001 .551 .941 .440 .005 .529 .000 .052 .438
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.470
** 1.000 -.009 .169 -.305
* .229 -.041 .366
** .147 .106
Sig. (2-tailed) .001 .949 .241 .031 .109 .777 .009 .309 .465
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.086 -.009 1.000 .461
** -.049 .385
**
.671
** -.179 -.102 -.279
*
Sig. (2-tailed) .551 .949 .001 .735 .006 .000 .215 .482 .050
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.011 .169 .461
** 1.000 -.235 .197 .403
** .005 -.268 .209
Sig. (2-tailed) .941 .241 .001 .101 .170 .004 .975 .059 .146
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.112 -.305
* -.049 -.235 1.000 .088 -.102 -.034 .203 -.068
Sig. (2-tailed) .440 .031 .735 .101 .542 .481 .814 .158 .640
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.393
** .229 .385
** .197 .088 1.000 .098 .275 -.004 .102
Sig. (2-tailed) .005 .109 .006 .170 .542 .498 .053 .978 .479
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.091 -.041 .671
**
.403
** -.102 .098 1.000 -.321
* -.164 -.237
Sig. (2-tailed) .529 .777 .000 .004 .481 .498 .023 .256 .097
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.563
**
.366
** -.179 .005 -.034 .275 -.321
* 1.000 .404
** .144
Sig. (2-tailed) .000 .009 .215 .975 .814 .053 .023 .004 .318
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.276 .147 -.102 -.268 .203 -.004 -.164 .404
** 1.000 -.019
Sig. (2-tailed) .052 .309 .482 .059 .158 .978 .256 .004 .895
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.112 .106 -.279
* .209 -.068 .102 -.237 .144 -.019 1.000
Sig. (2-tailed) .438 .465 .050 .146 .640 .479 .097 .318 .895
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.122 .177 -.109 -.087 .319
* .094 .024 -.032 .189 -.093
Sig. (2-tailed) .398 .220 .451 .548 .024 .516 .869 .826 .189 .519
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.408
** .211 -.150 -.227 -.020 .361
*
-.313
*
.428
** .214 .199
Sig. (2-tailed) .003 .142 .300 .113 .890 .010 .027 .002 .135 .167
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.410
**
.517
**
.467
**
.341
* -.228 .275 .154 .303
* .089 -.032
Sig. (2-tailed) .003 .000 .001 .015 .111 .054 .284 .032 .540 .825
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.023 .031 .220 .307
* -.088 .384
**
.294
*
.305
* -.016 .084
Sig. (2-tailed) .874 .830 .124 .030 .541 .006 .038 .031 .915 .563
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.523
**
-.432
** .272 .157 -.025 -.205 .475
**
-.401
**
-.332
* -.143
Sig. (2-tailed) .000 .002 .056 .276 .862 .152 .000 .004 .018 .323
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.509
**
.455
** -.083 .097 -.075 .511
** -.184 .686
** .223 .303
*
Sig. (2-tailed) .000 .001 .564 .504 .605 .000 .201 .000 .119 .033
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.259 .290
* -.100 -.061 -.136 .184 -.116 .409
** .201 .250
Sig. (2-tailed) .069 .041 .490 .676 .347 .202 .423 .003 .161 .079
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.461
**
.282
* .198 .321
* -.115 .497
** -.009 .537
** .095 .100
Sig. (2-tailed) .001 .048 .168 .023 .426 .000 .951 .000 .511 .490
N 50 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.007 -.107 .286
* .132 -.053 .088 .199 .082 -.034 -0.101
Sig. (2-tailed) .963 .460 .044 .360 .713 .543 .166 .571 .813 .484
N 50 50 50 50 50 50 50 50 50 50
*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
CSF1
CSF1_PPIA
EGFR
EGFR_PPIA
Mena
Spearman's rho CD68
MHCII
CD163
MR
IRF4
FN1
IL10
Mena_PPIA
IRF5
TNFa
iNOS
IL12
EGF
CSF1R
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IL12 EGF CSF1R CSF1 CSF1_PPIA EGFR EGFR_PPIA Mena Mena_PPIA
Correlation 
Coefficient
.122 .408
**
.410
** .023 -.523
**
.509
** .259 .461
** .007
Sig. (2-tailed) .398 .003 .003 .874 .000 .000 .069 .001 .963
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.177 .211 .517
** .031 -.432
**
.455
**
.290
*
.282
* -.107
Sig. (2-tailed) .220 .142 .000 .830 .002 .001 .041 .048 .460
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.109 -.150 .467
** .220 .272 -.083 -.100 .198 .286
*
Sig. (2-tailed) .451 .300 .001 .124 .056 .564 .490 .168 .044
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.087 -.227 .341
*
.307
* .157 .097 -.061 .321
* .132
Sig. (2-tailed) .548 .113 .015 .030 .276 .504 .676 .023 .360
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.319
* -.020 -.228 -.088 -.025 -.075 -.136 -.115 -.053
Sig. (2-tailed) .024 .890 .111 .541 .862 .605 .347 .426 .713
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.094 .361
* .275 .384
** -.205 .511
** .184 .497
** .088
Sig. (2-tailed) .516 .010 .054 .006 .152 .000 .202 .000 .543
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.024 -.313
* .154 .294
*
.475
** -.184 -.116 -.009 .199
Sig. (2-tailed) .869 .027 .284 .038 .000 .201 .423 .951 .166
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.032 .428
**
.303
*
.305
*
-.401
**
.686
**
.409
**
.537
** .082
Sig. (2-tailed) .826 .002 .032 .031 .004 .000 .003 .000 .571
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.189 .214 .089 -.016 -.332
* .223 .201 .095 -.034
Sig. (2-tailed) .189 .135 .540 .915 .018 .119 .161 .511 .813
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.093 .199 -.032 .084 -.143 .303
* .250 .100 -.101
Sig. (2-tailed) .519 .167 .825 .563 .323 .033 .079 .490 .484
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
1.000 .003 -.191 -.020 -.153 .082 -.050 -.202 -.444
**
Sig. (2-tailed) .983 .183 .890 .288 .573 .731 .160 .001
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.003 1.000 .126 .089 -.430
**
.369
** .099 .319
* -.077
Sig. (2-tailed) .983 .384 .537 .002 .008 .494 .024 .595
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.191 .126 1.000 .204 -.196 .241 .096 .477
**
.287
*
Sig. (2-tailed) .183 .384 .155 .172 .092 .508 .000 .043
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.020 .089 .204 1.000 .428
**
.398
** .181 .416
** .226
Sig. (2-tailed) .890 .537 .155 .002 .004 .208 .003 .114
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.153 -.430
** -.196 .428
** 1.000 -.329
* -.008 -.412
** .052
Sig. (2-tailed) .288 .002 .172 .002 .019 .955 .003 .720
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
.082 .369
** .241 .398
**
-.329
* 1.000 .751
**
.565
** -.017
Sig. (2-tailed) .573 .008 .092 .004 .019 .000 .000 .906
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.050 .099 .096 .181 -.008 .751
** 1.000 .182 .046
Sig. (2-tailed) .731 .494 .508 .208 .955 .000 .205 .752
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.202 .319
*
.477
**
.416
**
-.412
**
.565
** .182 1.000 .595
**
Sig. (2-tailed) .160 .024 .000 .003 .003 .000 .205 .000
N 50 50 50 50 50 50 50 50 50
Correlation 
Coefficient
-.444
** -.077 .287
* .226 .052 -.017 .046 .595
** 1.000
Sig. (2-tailed) .001 .595 .043 .114 .720 .906 .752 .000
N 50 50 50 50 50 50 50 50 50
*. Correlation is significant at the 0.05 level (2-tailed).
**. Correlation is significant at the 0.01 level (2-tailed).
CSF1
CSF1_PPIA
EGFR
EGFR_PPIA
Mena
EGF
Spearman's rho CD68
MHCII
CD163
MR
IRF4
FN1
IL10
IRF5
TNFa
iNOS
IL12
Mena_PPIA
CSF1R
 
 
Statistical values of correlations between target gene expression levels within FFPE ccRCCs are 
shown after normalization to the Ct values of CD45 or, when mentioned, to PPIA. Correlations 
were statistically analyzed using the Spearman’s Rho correlation test. 
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5.3  Efficient generation of multipotent mesenchymal stem cells from umbilical cord 
blood in stroma-free liquid culture 
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5.4  MAGE-C1/CT7 spontaneously triggers a CD4+ T cell response in multiple myeloma 
patients 
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